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ABSTRACT
A specific and sensitive radioimmunoassay for 4-OHA, a new anti-breast cancer 
agent, has been developed The assay uses a specific antisera to 4-OHA which can 
be used directly for the analysis of this drug in plasma samples.
A series of chemical reactions were carried out to prepare suitable haptens for this 
purpose. The antibodies were raised against two immunogens; first, 4-OHT-17P- 
hemisuccinate-17-ovalbumin and second 4-OHA-7a-carboxy-ethyl-thioether-7-ov- 
albumin.
The assay was successfully validated against a published 'indirect' RIA method for 
the measurement of 4-OHA.
Pharmacokinetic studies on 4-OHA were carried out in two animal species, rat 
(male and female) and rabbit. These studies were designed firstly t o assess the 
pharmacokinetic differences between male and female rats using the direct RIA 
and secondly to investigate plasma 4-OHA levels in male rats at various doses of 
the drug.
The RIA of 4-OHA should prove useful in more extensive experimental and 
clinical studies of 4-OHA.
Common Suffixes and Prefixes for steroids
Suffix or Prefix Définition
-al
-ane
-ene
-cl
-one
Aldeyde group 
Saturated hydrocarbon 
Unsaturated hydrocarbon 
Hydroxyl group 
Ketone group
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-hydroxy-(oxy-) 
-Keto-(oxo-) 
-deoxy- (desoxy-) 
dihydro- 
cis-
trans-
(X—
p -
epi-
A"
Hydroxyl group 
Ketone
Replacement of hydroxyl group by hydrogen 
Addition of two hydrogen atoms 
Spatial arrangement of two substituent on the 
same side of the molecule 
Spatial arrangement of two substitutes on the 
opposite sides of the molecule
Substituent which is trans to the methyl 
group at C-10
Substituent which is cis to the methyl 
group at C-10 
Isometric in configuration at any carbon 
atom except at the junction of two rings
Position of unsaturated bond
GLOSSARY OF SOME COMMON STEROIDS
Trivial name Svstematic name
Cholesterol  --------------------- Colest-5-en-3p-ol
Androstenedione (AD)------------------Androst-4-ene-3,17-dione
Testosterone (T)------------------------ 17p-Hydroxyandrost-4-en-3-one
Progesterone----------- ------------------Pregn-4-ene-3,20-dione
Oestrone (El)--------------------------- 3-Hydroxy-oestra-1,3,5( 10)-trien- 17-one
Oestradiol (E2)---------------------------Oestra-l,3,5(10)-triene-3,17p-diol
Oestriol (E3)----------------------------- Oestra-l,3,5(10)-triene-3,16a,17p-triol
Androsterone-----------------------------3a-Hydroxy-5a-androstan- 17-one
Corticosterone----------------------------11 p-21 -Dihydroxypregn-4-ene-3,20-dione
Deoxycorticosterone (DOC)-—-------- 21 -Hydroxypregn-4-ene-3,20-dione
Cortisone  ----------------------------17,21 -Dihydroxypregn-4-ene-3,11,20-trione
Cortisol------------------------------------11 p- 17,21-Trihydroxypregn-4-ene-3,20-dione
Pregnenolone-----------------------------3p-Hydroxypregn-5-en-20-one
Prednisolone---------- ---------------------Pregn-1,4-diene- lip -17a-21 -triol-3,20-dione
Dehydroepiandrosterone (DHA)------- Androst-5-ene-3p-ol-17-one
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INTRODUCTION
Breast cancer
Breast cancer is the most common and the most lethal malignancy of women 
living in Europe and in North America. It was initially believed to be a localized 
disease, spreading exclusively through invasion of the chest wall. It is now 
generally recognized that breast cancer should be regarded as a systemic disease, 
in view of its great propensity to metastatic dissemination, originating from even 
very small tumours (Brinkley et al. 1984; Rutqvist et al. 1984). The contributing 
factors may be: (1) genetic (hereditary disposition); (2) environmental (chemical 
carcinogens in food, water and air); (3) hormonal (oestrogens); (4) oncogenic 
(viruses); and (5) dietary (fat).
Imbalance of reproductive hormones (oestrogens, progesterone, prolactin, 
androgens) has been associated with the development of breast cancer. Also, 
metabolic hormones (growth hormone, insulin, thyroid hormone(s), 
glucocorticosteroids), melatonin, thymosin and prostaglandins have been related to 
the pathobiology of breast cancer (Kim et al.. 1976; Schaur et al.. 1979; Fazekas sL 
âl.» 1977; Angeli et al.. 1984 and Karmali et al.. 1983).
The risk factors for breast cancer have been reviewed in several papers (Thomas 
DB, 1980; Kelsey JL, 1979 and Petrakis NL, 1982).
Endocrine aspects of breast cancer
One-third of carcinomas of the breast in women are hormone dependent 
(McGuire, 1975). The properties of hormone dependency of breast tumours were 
first exploited by Beatson, 92 years ago, after the observation that surgical 
castration could induce regression of métastasés in patients with advanced disease 
(Beatson, 1896).
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Oestrogens (oestradiol, oestrone) induce mammary epithelial proliferation and 
thereby favour neoplasia, since carcinogens affect mitotic cells. The chance of 
cancer development has been correlated with the number of proliferating cells and 
their reaction to carcinogens (Miller et al.. 1980). The duration of epithelial 
stimulation also plays a role. Women with an early menarche (at up to 13 yr of age) 
and late menopause (at age 55 or later), who secrete oestrogens for a longer period 
during their lives, have an increased risk of developing breast cancer. Conversely, 
a shorter period of oestrogen secretion, i.e. late menarche (at age 16 or later), 
ovariectomy before menopause (at up to age 35), or early menopause (at up to age 
45), decreases the risk of breast cancer (Vorherr H, 1980).
Oestrogen biosynthetic pathways: The source of oestrogens differs 
according to the reproductive status of the patient. In premenopausal women, the 
ovary provides the major source of oestrogen. In ovarian granulosa cells, 
androstenedione (AD) and testosterone (T) are converted via the enzyme, aromatase 
into oestrone and oestradiol (Fig.l). The levels of aromatase in the ovary and thus 
total oestrogen production are stimulated by FSH. In postmenopausal women, the 
ovary produces only minimal amounts of either oestrone or oestradiol, and the 
adrenal gland becomes the major source of oestrogen precursors. These 
precursors, also called prehormones, are converted into oestrogens by the 
aromatase enzyme system (MacDonald et al.. 1967). This biosynthetic process 
takes place in fat, muscle, liver and the breast cancer tissue itself (Miller and Forest,
1974). Local oestrogen production can take place via one of two alternative 
pathways- the aromatase and sulphatase systems (Tseng et al.. 1983; Santner, 
1984). Recent studies (Santen, 1986) have shown that formation of oestrone from 
its sulphate is quantitatively more important than production from AD via 
aromatase. Oestrone sulphatase activity greatly exceeds that of aromatase in breast 
carcinoma tissues (Santner et al.. 1984).
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Aromatase: the enzyme system
The oestrogens, oestrone and oestradiol, are produced by aromatization of AD 
and T respectively. This conversion is carried out by the microsomal cytochrome 
P-450 dependent enzyme system generally referred to as aromatase. This enzyme 
is found predominantly in the gonads, adipose tissue and hypothalamus. The 
aromatization reaction (Fig. 2) is believed to proceed by two consecutive 
hydroxylations at C-19, followed by a third whose site is disputed (Thompson and 
Siiteri, 1974; Covey and Hood, 1982). Although evidence has been presented 
supporting a C-2 hydroxylation (Fishman, 1982; Hahn and Fishman, 1984), other 
experiments indicate that C-2 hydroxylation may not be 'obligatory' (Caspi et al.. 
1984). The activity of the system depends on two proteins: a flavoprotein, 
NADPH-dependent cytochrome P-450 reductase, and an aromatase specific 
cytochrome P-450 (Thompson and Siiteri, 1974; Osawa et al.. 1982). The 
flavoprotein, NADPH-dependent cytochrome reductase, of molecular weight 
approx. 80,000 daltons, can be obtained in homogeneous form from placental
microsomes (Henderson et al.. 1985). The cytochrome P-450aj.om component was 
identified as a protein of approx. 55,000 daltons, i.e. within the known range for 
P-450 isozymes.
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Fig. 1: Aromatization of androgens to oestrogens.
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Fig. 2: Probable route of aromatization of androstenedione (AD) to oestrone (El)
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Treatment of breast cancer
Until a decade ago, the radical mastectomy, meaning removal of the breast and 
the underlying muscles, was considered the sole therapeutic option for breast 
cancer. This treatment was based on the assumption that breast cancer is a single 
focus of disease for a considerable period of time. Breast cancer is now appreciated 
to be a disease which is localized for only a brief period and then disseminates into 
the lymphatic system. Another nonsurgical means of treatment is radiation therapy. 
While the breast remains intact in those women who received radiation therapy, this 
treatment can cause fibrosis and hardening of the affected breast. Moreover, 
radiation therapy also raises the possibility of tumour induction in the irradiated 
area. Some treatment schedules combine two or more of the following approaches: 
surgery, radiotherapy, chemotherapy or hormonal manipulation. This tiB&nent is 
then known as adjuvant therapy of breast cancer. The recent developments in 
chemotherapy and hormonal treatment of breast cancer are described briefly in the 
following sections.
C hem otherapy : A large panel of cytotoxic drugs showing significant
anti-neoplastic efficacy against breast cancer has become available during the last 
decade. Among the most widely used compounds are doxorubicin, 
cyclophosphamide, methotrexate, 5-fluorouracil, vinca alkaloids and, to a lesser 
degree, L-phenylalanine mustard, mitomycin C and thiotepa. These drugs are in 
fact cell poisons which generally kill those cells engaged in division. 
Consequently, most of these compounds affect tissues with rapid cell renewal, such 
as bone marrow, mucous membranes and hair follicles. Complete remissions are 
infrequent, so that cure cannot be regarded as a realistic objective for patients with 
overt métastasés, although palliation of symptoms can be achieved sometimes.
New hormonal treatments: All endocrine treatments for breast cancer either
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suppress the endogenous production of oestrogens or interact with their binding to 
oestrogen receptors (ER) at the cellular level. Many modalities of hormonal 
treatments have appeared, which are applicable to almost any patient. Moreover, 
additive treatments with pharmacological doses of oestrogens and androgens have 
been replaced by less toxic modalities, ie antioestrogens (tamoxifen) and progestins 
(medroxyprogesterone acetate and megestrol acetate). Tamoxifen, which is in 
widespread clinical use for the treatment of cancer in postmenopausal women, is an 
effective drug for the treatment of advanced breast cancer (Kiang and Kennedy,
1975). The mode of action of tamoxifen is ill understood, but it appears to act 
primarily through the oestrogen receptor system by inhibiting the biological effect 
of oestrogen in the tumour cell (Jordon and Koemer, 1975). Common side effects 
of tamoxifen are mild nausea, vomiting, and hot flushes.
Aromatase inhibitors: Recently, new perspectives have arisen in the field of 
hormonal suppressive therapy and clinicians now have at their disposal some potent 
drugs that can block the biosynthesis of oestrogens. These compounds are known 
as aromatase inhibitors.
Non-steroidal inhibitors of aromatase are relatively heterogeneous as a 
group chemically, which nevertheless exhibit some common features. The best 
known non-steroidal inhibitor is aminoglutethimide (AG) which is devoid of any 
agonist hormonal property and whose activity as an aromatase inhibitor was 
demonstrated by Chakraborty et al. (1972). AG reduces circulating levels of 
oestrogens in postmenopausal women to the same extent as surgical adrenalectomy 
(Santen and Brodie, 1982; Vermeulen et al.. 1983). AG exerts at least two 
enzymatic blockades by binding to cytochrome P-450 and interfering with steroid 
hydroxylations which result in the reduction of oestrogen production. The first 
enzymatic blockade is at the level of the adrenals, and consists of the inhibition of
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desmolase (converting cholesterol into pregnenolone), while the second is at the 
level of aromatase (converting androgens into oestrogens) in peripheral tissues 
(Uzgris et al.. 1977). The results of many clinical studies indicate that AG (plus 
cortisol) has rendered surgical adrenalectomy obsolete in postmenopausal patients 
(Harris, 1985). However, the usefulness of AG is limited by toxicity and other 
side effects such as lethargy, drowsiness and rash (Smith et al.. 1981). Other 
non-steroidal inhibitors of the aromatase system include the heterocyclic 
compounds with a ring nitrogen. Among the better characterized inhibitors of this 
group are the antifungal agents ketoconazole, miconazole and clotrimazole (Fig. 3) 
(Mason et al.. 1985). These three compounds are all imidazole derivatives, and it is 
thought that the inhibition results from formation of a complex between the 
unhindered nitrogen of the imidazole group and the heme iron of the oxidized 
cytochrome, preventing subsequent reduction (Wilkinson et al.. 1972; Hajek et al.. 
1982).
The main problem with non-steroidal inhibitors of aromatase is the lack of 
specificity. AG inhibits cytochrome P-450 and interferes with several 
hydroxylation steps in steroid biosynthesis. Thus, desmolase, 11-hydroxylase, 
21-hydroxylase, 18-hydroxylase as well as aromatase are inhibited by AG (Uzgiris 
et al.. 1977; Whipple ÊLâl-, 1978).
Another group of non-steroidal compounds which can inhibit the aromatase 
enzyme and these are the dicyclohexane derivatives (Verhoeven et al.. 1983). They 
have a superficial resemblance to the non-steroidal oestrogens (e.g. 
diethylstilbestrol) and, more remotely, anti-oestrogens such as tamoxifen (Fig. 3).
Finally, new compounds of non-steroidal structure such as CGS 14796C, or 
cis-l-[(l-imidazolyl)methyl]-cyclohexyl)methyl)imidazole succinate (Schiavo et al..
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1988) and CGS 16949A, or {4-(5,6,7,8-tetrahydroimidazole[l^ a]-pyridin-5-yl) 
benzonitrile monohydrochloride } (Schieweck et al.. 1988) are being developed 
and tested as potential inhibitors of aromatase. Both of these compounds are 
showing promising potency and specificity as aromatase inhibitors.
Steroidal inhibitors of aromatase: Steroid substrate analogues constitute 
the largest group of aromatase inhibitors. These compounds which act as substrates 
for the enzyme interfere with androgen aromatization on binding to the enzyme at 
the active site. The conversion of androgens to oestrogens is a unique reaction in 
the biosynthesis of steroids as it involves aromatization of ring A of the steroid 
molecule. Also, aromatization is the last in the series of steps (Fig. 4) in the 
biosynthetic reactions from cholesterol to the oestrogens. These inhibitors would 
be expected to be more specific for oestrogen biosynthesis than inhibitors which 
interfere with steroid hydroxylations by binding to cytochrome P-450 (e.g., 
aminoglutethimide, imidazole compounds).
Very recently, a new irreversible aromatase inhibitor, 6-methylenandrosta-l,4- 
'diene-3,17-dioney was shown to be highly effective against DMBA-induced 
mammary tumours in rats (Zaccheo et al.. 1989). This compound was found to 
possess androgenic activity which makes a positive contribution to its antitumoral 
effect. In general, optimal inhibition is found with derivatives of AD (Fig. 5), the 
reason being that binding to the protein is favoured by the 3 and 17 ketone groups, 
a C4-C5 double bond and the angular methyl group (C-19) on C-10 (Schwarzel êî 
âl., 1973).
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Fig. 5: Some inhibitors of aromatase of steroidal structure.
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4-Hydroxy-4-androstene-3,17-dione (4-OHA)
4-Hydroxy-4-androstene-3,17“dione (4-OHA, Fig. 6) was selected as the most 
potent and specific inhibitor of the aromatase system from over 200 potential 
compounds and was shown to have high potency as an aromatase inhibitor in vitro 
and in vivo (Brodie etal.. 1976; Brodie et al.. 1977), being approximately 60 times 
more potent in vitro than aminoglutethimide (Wing et al.. 1985). 4-OHA has also 
shown to have activity against human ovarian aromatase in granulosa cell cultures 
(Koos et al.. 1985).
HO
Fig. 6: The aromatase inhibitor: 4-Hydroxyandrostenedione
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Because of its potency in vitro, high efficacy in animal models and ease of 
synthesis, 4-OHA was selected for the first clinical trial of a specific aromatase 
inhibitor. The drug is not only a powerful inhibitor of aromatase, but it also has 
low toxicity, and it does not cause any endocrine side effects.
Phase I and phase II clinical trials of the drug have been succesfiilly carried out 
In the initial report, eleven patients with histologically proven advanced progressive 
disease with measurable lesions were treated with intramuscular injections of 500 
mg of 4-OHA for 3-20 weeks (Coombes et al.. 1984). None had received 
endocrine therapy or chemotherapy within four weeks of starting 4-OHA treatment 
Eight patients received one injection per week and three patients received one 
injection every two weeks. No adverse effects of 4-OHA were encountered except 
for pain at the site of injection in three patients which necessitated reduction in the 
frequency of injections and hot flushes experienced by two patients. Tumour 
oestrogen receptor concentrations were unknown for six patients, and five patients
had oestrogen receptor positive tumours. The mean serum oestradiol (E2) 
concentration of five patients decreased significantly 24 hours after treatment and 
was 20% of the pretreatment level after 7 days (Fig.7). Partial or complete 
remission of measurable lesions occurred in four patients (36%). Three of the 
responders had responded previously to endocrine therapy but had relapsed, and 
the fourth patient had oestrogen receptor positive tumours. Seven other patients did 
not respond to 4-OHA therapy although the disease was stabilized in one. 
However, none of these, except one, had responded to previous endocrine therapy.
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Fig.7: Effects of a single dose of 500mg 4-OHA on plasma oestradiol in 
5 patients with breast cancer (Coombes et al., 1984).
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The results obtained from the first clinical trial of the drug suggested that this 
aromatase inhibitor may be beneficial to women with hormone-dependent metastatic 
breast cancer. However, in a larger study (phase II report), the biological activity 
of the drug was confirmed (Goss et al.. 1986) and it was shown that 4-OHA was 
capable of markedly reducing plasma oestradiol levels and producing tumour 
regression in postmenopausal patients with advanced breast cancer. In addition, 
this report was the first direct evidence that selective inhibition of oestradiol 
synthesis is important in the endocrine treatment of postmenopausal breast cancer. 
In this report, fifty eight patients with advanced postmenopausal breast cancer were 
treated with 500-1000 mg of 4-OHA (i.m). Fourteen (27%) of the 52 assessable 
patients responded to treatment. In 10 (19%) patients the disease stabilized, and in 
28 (54%) patients the disease progressed. In a more recent study conducted by 
Murray et al.(19881.13 postmenopausal patients failing other hormonal therapy for 
advanced breast cancer have been treated with 4-OHA 250mg i.m. fortnightly. The 
study showed that clinical response has been observed in 3 patients with disease 
stabilisation in one. Progression has occured in 6 patients and 3 were not then 
assessable. Therapy has been well tolerated and apart from transient pain at the 
injection site there have been no significant side effects.
Toxicity: The toxicity findings in phase II of the clinical trials revealed that the 
major side effect due to 4-OHA was local reaction at the injection site. Sterile 
abscesses occurred at the injection site in 6 patients and painful lumps occurred in a 
further 3 patients. However, the incidence of painful lumps decreased as the 
technique of administration was modified e.g. slow rate of injection. Four patients 
had transient, mild lethargy which appeared to be treatment related. Perioral 
oedema occurred in one patient, this was resolved within 48 hours of occurrence. 
No other systemic toxicity was noted.
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Endocrine effects of 4-OHA: One month after treatment with 4-OHA, the 
plasma levels of oestradiol were suppressed as much as 65% of the pretreatment 
level. No further change in oestradiol levels after 2 or even 4 months of treatment 
was noted.
The following hormones were measured one month after treatment with 
4-OHA: oestrone, LH, FSH, Dehydroepiandroserone sulphate (DHAS) and Sex 
Hormone Binding Globulin (SHBG) binding capacity. There was no significant 
fall or rise in any of these hormones. The fact that no change in SHBG capacity 
occurred after treatment with 4-OHA indicates that the drug has no effect on the 
androgens. DHAS levels in the plasma are a relatively stable marker of adrenal 
activity and are closely related to urinary free cortisol levels (Santen et al.. 1977). 
Since no effect occurred on DHAS plasma levels after treatment with 4-OHA it is 
unlikely that the drug affects adrenal function.
O ral 4-OHA: The major side effect observed when 4-OHA was given 
parenterally was local abscess formation. This led to the development of an oral 
dosage regime (Cunningham et al.. 1987). The response rate was similar to that of 
parenteral 4-OHA and the data obtained suggest that 250 mg p.o daily is nearly as 
potent as 500 mg daily in suppressing plasma oestradiol. With regard to toxicity, 
27 of the 30 patients evaluated had no side effects. One patient developed an 
erythematous skin rash and one patient facial swelling. The third patient developed 
a transient leucopaenia.
In general, the side effects related to parenteral and oral 4-OHA treatment are 
mild. The vast majority of patients , over 170 patients, experienced no toxic 
reactions (Coombes et al.. 1984; Goss et al.. 1986). On the other hand, the side
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effects reported with AG treatment were frequent. Seventy of the 213 patients 
treated with AG developed drowsiness and lethargy, 49 patients had skin rashes 
and 32 patients experienced nausea. In addition, there is no need for corticosteroid 
therapy with 4-OHA.
Mechanism of action of 4-OHA: The site of inhibition by 4-OHA in the 
conversion of cholesterol to oestradiol is shown in Fig. 4. Experiments in monkey 
revealed that there was no effect of 4-OHA on the interconversion of the androgens 
(AD and T), of the oestrogens (oestrone and oestradiol), or the conversion of AD to 
dihydrotestosterone (Brodie and Longcope, 1980). This indicates that the enzyme 
systems involved in such conversions are not affected by 4-OHA at the dose used 
(50 mg/kg). No effects on the metabolic pathway between progesterone and AD 
was observed in ovarian microsomes incubated with progesterone in the 
presence of 4-OHA (Brodie and Longcope, 1980). The metabolism of DHA to AD 
was also not affected by 4-OHA.
According to Newitt and Robinson (1986), 4-OHA is a powerful active-site 
directed inhibitor of the aromatase system which means that the drug is a suicide 
inhibitor of aromatase. The exact mechanism of this inactivation is unknown.
However, the natural substrate AD during its conversion to oestrone (Ej) is known 
to undergo two successive oxidations at C-19 (Fig. 2) to give 19-hydroxy and 
19- 0X 0 intermediates. According to the same authors , 19-nor-4-OHA did not 
inactivate aromatase, so he suggested that oxidation at the C-19 methyl, may be 
involved in the mechanism of inhibition by 4-OHA. Newitt and Robinson (1986) 
have synthesized and tested 4-hydroxyandrost-4-ene-3,17,19 trione against human 
placental aromatase. They found that this compound caused time-dependent loss of 
aromatase activity only in the presence of the cofactor NADPH. These findings
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support the hypothesis that 4-OHA inactivation of the aromatase enzyme involves 
oxidation at C-19. The 19-oxo analogues requirement for cofactor suggests a third 
oxidation may be required to form the inactivating species. Further support for 
Newitt and Robinson's suggestion can be found in the findings of Fishman and 
Goto (1981) and Akhtar et al (1982). The workers showed that the 2p-position is 
the site of the third hydroxylation during the conversion of AD to oestrone. Covey 
and Hood (1982) postulated that 4-OHA undergoes metabolic activation in which 
the 4-hydroxy group leaves as water while the aromatase remains attached to the 
steroid resulting in its inactivation (Fig. 8).
It is evident from the above studies that further work is needed to elucidate the 
mechanism of inhibition of aromatase by 4-OHA.
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Fig. 8: Proposed mechanism of inactivation of aromatase by 40HA 
(Covey and Hood, 1982).
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Metabolism of 4-OHA: A comprehensive study on the metabolism profile of 
4-OHA has recently been carried out in order to determine the fate and biological 
properties of the metabolites (Foster et al.. 1986). Prior to this, some information 
on the metabolism of 4-OHA had been published. Brodie et al (1981) found that 
following i.v administration of 3H-4-OHA to male Rhesus monkeys, only 6-7% of 
the total radioactivity of non-acidified blood samples taken up to 3 hours after 
injection could be extracted by ethylacetate (this means the water-soluble conjugates 
such as glucuronides or sulphate were the major metabolites 3 hours after 
injection). In the same study, trace amounts of 4-OHT were isolated in the material 
extracted with ethyl acetate. The ratio of 4-OHA to 4-OHT was 6:1.
Subsequently, Marsh et al.(19821 reported on the metabolism of 4-OHA in vitro 
and in vivo in the rat. In ovarian microsomes, 4-OHT was the major metabolite of 
^H-4-OHA and only a trace of 4-OHEl was identified. However, when 
3H-4-OHA was injected i.v into female rats, 20% of the total radioactivity in the 
blood could be extracted with ethylacetate one hour after the injection. The 
radioactivity comprised of 1.4% of 4-OHA, 0.5% of 4-OHT and as much as 18% 
of 3p-OH-5a-androstan-4,17-dione. The latter compound was also isolated as a 
metabolite of 4-OHA from aerobic cultures of mycobacterium Phleily (Tomorkeny 
et al.. 1975).
Recently, Foster et_al.(1986) have classified the metabolism of 4-[l4c]-4-OHA 
in rat hepatocytes into two phases. They suggested that phase I metabolism of the 
drug in the hepatocytes isolated from phenobarbital-treated rats follows well known 
pathways (Testa and Tenner, 1976), but the formation of the metabolites of 4-OHA 
was much more rapid, extensive and complex, variously involving one reduction 
(compounds 1 and 2, Fig. 9) and two reductions (compound 3), hydroxylation
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(compound 4), hydration (compound 5) and hydroxylation plus one (compound 6) 
and two (compound 7) reductions. These metabolites were identified either by 
synthesis or tentatively by mass spectrometry. Compound 1 in Fig. 9, 
3p-hydroxy-5a-androstan-4,17-dione, was the major metabolite in phase I and 
accounted for 18% of the radioactivity in the ethylacetate extract. This finding is 
similar to previous results (Marsh et al.. 1982) in female rats. The distinctive 
feature of phase I metabolism of 4-OHA in this study was the speed at which these 
metabolites were produced. After 5 minutes of incubation approximately 99% of 
the 4-[14C]-4-0HA had disappeared.
The major phase II metabolite of 4-OHA was its glucuronide, which has been 
isolated, and its methylated derivative was characterized by chemical 
ionization-mass spectrometry. The formation of the glucuronide was eventually 
very extensive (80%). However, the authors noted that the extent and pattern of 
glucuronidation was likely to be a function of the inducer used (Ullrich and Bock, 
1984). No 4-OHT was detected as a metabolite in this study either as a conjugate 
or free steroid.
In another study (Goss etal., 1986 b), 4-OHA glucuronide was identified and 
quantified as the major urinary metabolite in humans and in the bile of rats. This 
glucuronide was identified by chemical ionization-MS of the permethylated 
derivative and quantified by first converting it enzymically into 4-OHA, then 
determining 4-OHA by capillary column GC-MS of the perfluorotolyl derivative 
using 4-Oh A’^  as internal standard.
The abundance of 4-OHA as a glucuronide could mean that 4-OHA glucuronide 
may function as a pro-drug or a storage substance, from which 4-OHA is released 
by the action of p -glucuronidase. This may explain the prolonged low levels of 
oestrogens in patients plasma after administration of 4-OHA.
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Fig. 9: Phase I metabolites of 4-OHA produced by rat hepatocyte.
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Assay of 4-OHA
Extensive and rapid conjugation of 4-OHA may be responsible for the limited 
success achieved to quantify 4-OHA in plasma. Jarman et al.fl985^ developed and 
used a novel specific assay to measure 4-OHA in the plasma of rats treated with 
4-OHA. The assay was based on gas chromatography and mass spectrometry. 
However, the detection limit of this assay was only 1 pg/ml, and this level was 
observed 24 hours after a single subcutaneous dose (50 mg/kg). Later studies 
indicated that assays would require much higher sensitivity and subsequent attempts 
to measure the drug in rat plasma using a capillary gas chromatography-mass 
spectrometric assay were more successful (Goss et al.. 1986b), where levels of 50 
ng/ml were measured. An unpublished chromatographic method (personal 
communication) for the measurement of 4-OHA has also been developed at 
Ciba-Geigy (Basle), but this method failed to detect drug levels below 
approximately lOng/ml. The first report of a radioimmunoassay (RIA) for 4-OHA 
has been published recently (Dowsett et al.. 1987). Plasma levels of 4-OHA were 
measured by adapting an RIA for AD which utilizes antibodies with a 25% 
crossreactivity with 4-OHA. The method required a chromatographic separation of 
4-OHA from AD. Lipidex 5000 in trimethyl-pentane-iso-propyl alcohol (1:5) was 
used to separate 4-OHA fi’om AD. This method allowed measurement of levels 
within the therapeutic range, in one study 0.7-23.2 ng/ml. The serious limitation of 
this procedure is that since the antisemm used in the assay was raised to AD rather 
than to 4-OHA, the potential cross-reactions of some endogenous steroids and 
metabolites of 4-OHA were therefore greater than if a homologous antiserum was 
used. However, these cross-reactions were probably minimized by 
chromatography which is time consuming and susceptible to errors and losses of 
steroids. Finally, in a recent publication (Parr et al.. 1988), 4-OHA levels in rats 
were estimated by using a bioassay (sensitivity 10 ng/ml) based on the inhibition of 
aromatase activity.
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Current techniques for steroid assay
Methods for the quantitative determination of steroids can be divided into the 
following categories: colorimetric, fluorometric, chromatographic; gas 
chromatography (GC) and high performance liquid chromatography (HPLC), 
radioisotope methods (double isotope derivative dilution method) and 
immunoassays methods (RIA).
In the last decade, the use of methods based on colorimetry, fluorometry and to 
a lesser extent double isotope derivative dilution has been very limited. However, 
methods based on chromatography are more important because of their greater 
sensitivity. The most common chromatographic methods are GC and HPLC. 
HPLC is a technique that utilizes high pressure to force solvents through a column. 
It is an extremely versatile technique in the sense that it may employ the principles 
of adsorption, partition, ion exchange, exclusion and affinity chromatography. 
HPLC offers many advantages over traditional liquid chromatography such as high 
resolution, increased speed, increased sensitivity and easy sample recovery. Under 
particular experimental conditions, the elution times relative to the internal standard 
are used for identification of individual steroids. Quantitation is generally carried 
out by uv, fluoremetric or EC detectors and relative peak heights or areas compared 
to standards can be determined for the respective steroids. Several methods for the 
separation and determination of steroids by HPLC have been reported (Hunter êî 
âl-, 1979; Heftmann and Hunter, 1979; Eibs and Schonesohfer, 1984). GC on the 
other hand, is designed to separate and quantitate volatile compounds in a heated
column (up to 400 ®C). The mobile phase is an inert carrier gas which sweeps the 
volatile compounds through the column to a detector (flame ionisation or electron 
capture detection) for quantitation. The technique offers the advantages of speed,
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relative sensitivity, accuracy, precision and specificity (Wotiz and Chattoraj, 1973).
Most of the techniques described above are time-consuming and require 
expensive equipments and consistant service. High sensitivity and high throughput 
in steroid determinations arrived with the development of RIA.
Radioimmunoassay:
RIA is currently the most widely used technique for routine measurements of 
steroid hormones in plasma because of its specificity, simplicity and sensitivity 
(Nieschlag and Wickings, 1975). RIA methods for most of the common steroids 
have been developed (Ratcliffe, 1982; Hamalainen, 1982).
The first report of the RIA technique was published by Yalow and Berson 
(Yalow and Berson, 1959; 1960). The technique was developed by accident as 
they were attempting to separate the radiolabelled insulin that had been metabolised 
in vivo from that which had remained intact.
The publication of the first RIA by Yalow and Berson (1960) was the most 
significant event in the development of immunoassays because this publication 
aroused considerable interest, particularly amongst those actively pursuing research 
in the field of endocrinology. Today, immunoassays enjoy an almost 
unprecedented popularity as methods of choice for sensitive quantitation of 
biological materials and drugs. Immunoassays currently, use a variety of detection 
systems, such as radioisotopic measurement (RIA), fluorescence (FIA), enzyme 
(EIA) and chemiluminescence (LIA). A source of confusion is the widespread 
practice of using acronyms such as ELISA (enzyme-linked immunosorbent assays) 
and IRMA (immunoradiometric assays) to the current display of FACIA (particle 
counting immunoassays), IFMA (immunofluorimetric assays), RAST
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(radioallergosorbent tests) etc .
RIA combines the specificity of immune reactions with the sensitivity of 
radioisotope techniques and therefore, it can offer the required sensitivity , 
specificity and reliability. The principle of RIA ( Yalow and Berson, 1959; Eldns gl 
al, 1968; Cameron et al.. 1975; Hunter and Corrie, 1983) is based on the 
competition between radioactively labelled and unlabelled antigen for a fixed but 
limited number of binding sites on antibody molecules. Under standard conditions 
the amount of labelled antigen bound to antibody will decrease as the amount of 
unlabelled antigen in the sample increases, for example:
4Ag* + 4Ab 4Ag*Ab
4Ag + 4Ag* + 4Ab_______ 2Ag* Ab + 2AgAb + 2Ag* + 2Ag
12Ag + 4Ag* + 4Ab Ag*Ab + 3AgAb + 3Ag* + 9Ag
(where Ab, Ag, Ag* and AgAb represent one equivalent of antibody, unlabelled 
antigen, labelled antigen and antigen-antibody complex respectively).
Using known amounts of Ag and a fixed amount of Ag* and Ab, a standard 
curve may be constructed. Unknown amounts of antigen in biological test samples 
are obtained from such curves by interpolation.
In order to develop an RIA, there must be available the following: (1) pure
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antigen ; (2) radiolabeled antigen; (3) antibody to the antigen that is both specific 
and potent; (4) a good system for the separation of the bound antigen-antibody 
complex from the free antigen; and (5) radioactivity counter. Pure antigen is 
required for standard samples production of labelled antigen and the production of 
a specific antiserum. Probably, the most critical single factor for the development 
of a sensitive and specific RIA is the production of a good antiserum. This is 
achieved by immunizing a selected vertebrate with the molecule of interest. For 
compounds of low molecular weight, such as 4-OHA, a major problem is that the 
molecules themselves are not antigenic. They must be coupled to a larger antigenic 
molecule (carrier protein) on which they will provide a stmcture (epitope) that will 
be recognized by the immune system of the animal which is to produce the 
antibodies. The molecule attached to the carrier protein is known as a hapten and 
the protein conjugate is known as "immunogen". Proteins to which steroids are 
frequently coupled in this way are bovine serum albumin (BSA), keyhole limpet 
haemocyanin (KLH) and ovalbumin.
Coupling steroids and similar compounds to protein molecules is not a direct 
process, because steroids contain few functional groups and reactions are required 
to minimise protein dénaturation. The use of a chemical 'bridge' which forms a 
link between the steroid and the protein is necessary to increase the antiginicity of 
haptens. These chemical'bridges'(Fig. 10) are usually bifunctional compounds, 
so that one functional group can react with the steroid and the other with the 
protein. Methods used for the formation of a peptide link between the steroid 
derivative and the polypeptide chain of the carrier are mainly methods developed to 
join amino acid residues into a polypeptide chain. However, the reaction in the case 
of steroid protein complex is much easier because the steroid derivative is the only 
carboxylic acid present The conjugation reaction can be achieved by three principle 
methods:
(1) the mixed anhydride reaction (Erlanger et al.. 1957) which was used in
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the present work (2) the EDC or 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide 
hydrochloride reaction (Kurzer and Douraghi-Zadeh, 1967) and (3) the use of 
hydroxysuccinimideesters (Andersonetal.. 1964).
The specificity of the antiserum for its hapten is influenced by the point of 
attachment of the bridge to the steroid. It is well established that an antibody will 
recognize the part of a hapten which is furthest from the site of conjugation to 
protein (Landsteiner, 1945). Thus, for steroids, if attachment is through position 
3, structural features of rings B, C and particularly D are well recognized. If 
attachment is through position 17, features in rings C, B and particularly A become 
the dominant determinants of the specificity of the antiserum. Before injecting a 
conjugate into an animal, the conjugate is mixed with Freund's complete adjuvant 
which consists of a stabilizing emulsifier and a mineral oil, together with inactivated 
bacteria (BCG). These are thought to sensitize the immune system of the animal 
and facilitate the production of antibodies. The practice is to use 'complete' 
adjuvant for the primary immunisation, but 'incomplete' adjuvant (without BCG) 
thereafter. The most successful schedule described is a single primary 
immunization followed by boosters at monthly intervals. Hum (1971) has 
indicated that leaving the primed animals for a long time before boosting them is 
worthwhile in order to obtain antiserum of high titre. This has also been the 
experience of other workers in this laboratory.
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Fig. 10. A typical steroid antigen 
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The properties of individual collections of serum from the same animal must be 
assessed by measuring the titre, avidity and specificity. An antiserum dilution 
curve is used to determine the titre of the antiserum which is defined as that dilution 
of the antiserum which achieves 50% of the maximum binding of a fixed amount of 
the labelled antigen. The titre indicates the relative concentration of antibodies and 
says little about its quality. Avidity, which indicates the quality of an antiserum, is 
critical in terms of the potential performance of the assay (Jackson and Ekins, 
1986). This information can be obtained indirectly by setting up an antiserum 
displacement curve which can be achieved by adding a small amount of unlabelled 
antigen to tubes whose composition is identical to those used to derive the 
antiserum dilution curve. The avidity is indicated by the extent of shift to the left by 
the displacement curve. Specificity is the most important quality of an antiserum 
particularly when the hapten involved is a steroid. Specificity of an antiserum can 
be determined by constructing the cross-reactivity curves. These are explained in 
detail in Chapter 4.
The separation of the antibody-bound fraction of antigen from that remaining 
free in the solution is the final stage in RIA before counting and is known as phase 
separation. RIA can use all types of separation techniques which involve the 
insolubilisation of either fraction of label followed by sedimentation of the 
insolubilised fraction. The ideal separation system should allow complete 
separation of one fraction from the other and should not disturb the equilibrium 
between them so that misclassification is minimized. A number of methods are 
used for achieving phase separation (Ratcliffe, 1974) these are: (a) chemical 
precipitation; (b) chromatography; (c) adsorption; (d) solid phase; (e) immunology. 
The non-specific separation of the antibody fraction (e.g. protein precipitation with 
ethanol), or non-specific separation of the antigen fraction (e.g. adsorption with 
charcoal), are being increasingly superseded by specific precipitation methods, such
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as immunoprécipitation, using a second antibody reaction, and separation using 
solid-phase reagents. However, dextran coated charcoal offers a rapid, efficient 
separation of free and bound antigen.
The significant feature of RIA with reference to other immunoassays is the use 
of a radioisotopic label to discriminate between the antibody bound fraction and the 
free fraction of the antigen. The incorporation of atoms emiting either p or
y-radiation have been the most widely developed techniques. The most commonly 
used radioisotope at present is ^^ I^, this isotope is detected by scintillation crystals 
and does not need any additional preparation. The use of for steroids can 
cause problems because of the bridge effect which may lead to reduction in 
immunoreactivity. Furthermore, steroids are often difficult to iodinate. However, 
most steroids are labelled by the incorporation of either ^H or l^C atoms. Such 
labels require additional sample preparation before detection by liquid scintillation 
counting. Other non-isotopic labels have also been used in ELISA (enzymes) and 
LIA (luminescent) immunoassays.
Monoclonal antibodies
Every specific antibody produced by the immune system in response to any 
given immunogen will be produced by lymphocytes derived from a single 
lymphocyte. Because of the multiplicity of antigenic sites on any single 
immunogen, or because of the impurities in the immunogen...etc., a large number 
of different and distinct lymphocytes may be stimulated following immunisation. 
As a consequence, antisera invariably contain a heterogenous mixture of different 
antibodies of varying specificity and affinity. These are called polyclonal 
antibodies.
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A recent development of some considerable interest has been the production of 
monoclonal antibodies which are derived from a single cell line (Kohler and 
Milstein, 1975). These antibodies are produced by injecting specific strains of mice 
or rats with the immunogen. Lymphocytes from the spleens of these animals are 
fused with appropriate myeloma cells and then grown in culture. The hybrid cells 
are selected out and propagated. These cells can be injected into the peritoneum of 
sensitized rodents in which they will produce an ascites tumour with fluid rich in 
antibodies which can be used in immunoassays. However, in addition to the time 
and cost the monoclonal antibodies production suffers, there are two major 
problems in the application of monoclonal antibodies to steroid RIAs. Firstly, 
cross-reaction can be a serious problem and can limit the usefulness of the 
monoclonal antibodies. The reason is that all the antibodies are identical because 
they are directed against an 'epitope' which may be found in many other steroids. 
Secondly, there is a great chance of producing antibodies with low affinity.
AIMS OF THE PRESENT STUDY
The success in clinical trials of 4-OHA as an effective drug in the management 
of postmenopausal patients with breast cancer without any endocrine side effects 
has necessitated the search for a specific, simple and reliable assay for the 
measurement of 4-OHA. Such an assay would facilitate the plasma 
pharmacokinetic studies and other biochemical investigations of the drug in chosen 
animal species and in man. The data generated therefrom would provide the basis 
for optimising the dose and route of administration of 4-OHA and to devise the 
most effective overall therapeutic regimen for the drug.
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The aim of the present study was to develop an immunoassay for the 
measurement of 4-OHA in plasma using a specific antiserum to the drug. Such an 
assay must be sensitive and specific in order to overcome the difficulties often 
associated with steroid immunoassays. The analysis would then be applied to 
study the plasma protein-binding and pharmacokinetics of 4-OHA and if time 
permitted the excretion and distribution of the drug in the rat and where possible in 
the human.
A further possible application of the above antiserum would be uses, as a 
biochemical probe, to investigate the distribution of 4-OHA in the body and the 
interaction of this drug with cellular and subcellular components.
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CM A PTEE T W O
MATERIALS AND METHODS
Materials
Steroids: 4-OHA was kindly provided by Ciba-Geigy (Horsham,UK). 
4-OHT and 3 p-hydroxy-5a-androstan-4,17-dione were kindly provided by The 
Institute of Cancer Research (Dr. M. Jarman). AD, T, testosterone hemisuccinate 
(THS), cortisol, corticosterone, cortisone, oestradiol, oestrone, 
dehydroepiandrosterone (DHA), deoxy-corticosterone, progesterone, 
17a-hydroxyprogesterone were purchased from Sigma (London) Chemical Co.
Ltd.,Poole, Dorset, UK. 4-Hydroxy-oestradiol (4 -OHE2), 4-hydroxy-oestrone 
(4-OHEj) were purchased from Steraloids Ltd. Croydon, UK.
Donkey anti-sheep IgG labelled with N-(4-aminobutyl)-N-ethylisoluminol 
hemisuccinamide second antisera was prepared in the Biochemistry Department 
(Dr. W.Aheme). 4-OHT-17-hemisuccinate used for the conjugation to 
thyroglobulin (TG) was the same product used for the production of 4-OHA 
antiserum. Thyroglobulin, isobutylchloroformate. Tween 20, equine heart 
cytochrome c microperoxidase II (sodium salt) and hydrogen peroxide were 
obtained from Sigma Chemical Co., Poole, Dorset. All other reagents were 
purchased from BDH Chemicals Ltd. Polystyrene disposable measuring cuvettes 
were obtained from Clinicon (UK) ltd., (Petworth, Sussex).
Radioactive [1,2,6,7 (n)-^H] AD with specific activity of 95 Ci/mmol and 
[l,2,6,7(n)-3H] T with specific activity of 95 Ci/mmol were obtained from 
Amersham International PLC, Bucks, England.
Lipidex-5000 was purchased from Packard Ins. Co. Inc. and stored in 
methanol at 4 °C. Precoated thinlayer chromatography (t.l.c.) plates were
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purchased ftom E.Merck, AG, Darmstadt Silica gel 60 Merck 7734,70-230 mesh 
and all organic solvents were analytical grade and were purchased from the BDH 
Chemicals Ltd., Poole, Dorset, U.K. unless otherwise stated . Water was glass 
distilled and, in the main, used fresh.
Disposable glass pipettes used for column chromatography using Lipidex 5000 
were obtained from John Poulten, Barking, U.K .
The mass spectrum used for the characterisation of products synthesised in the 
laboratory was Finnigan 400 series GC-MS linked to a 6110 series data system,
probe: direct insertion heated up to 300°C.
All chemicals used in conjugations were obtained from Sigma. AD antiserum 
(HP/S/6651A) was generously provided by Guildhay Antisera Ltd, Guildford, 
U.K. All other compounds and chemicals used were of laboratory reagent grade 
unless otherwise stated, and were used as purchased.
Chromatographic Methods:
a) Thin Layer Chromatography (t.l.c.)
Pre-coated plates (silica gel 60 F254) were used for all t.l.c. work which was 
used to characterise and investigate the purity of the synthesised steroids. The 
plates were 0.25 mm in thickness, and 20 cm x 20 cm in dimension and were
(not)
activated for 10 minutes in a pre-heated oven ) before use. The steroids were applied 
in ethanol as a spot, one inch above the lower edge of the plate with a minimum 
distance of 1 inch between the steroids in the same line. The t.l.c. tanks were kept 
with the developing solvent systems in an enclosed environment for at least 1 hour 
to ensure a fully saturated atmosphere before transferring the plates into the t.l.c.
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tanks. For t.l.c. approximately 150 ml of solvent mixture was used routinely. 
These were freshly prepared for every run and the plates were removed from the 
tank when the solvent front was approximately 1 inch from the top edge of the 
plate. The visualisation of the steroids was achieved by examining the plates, which 
contain a fluorescence binder, under a single wavelength (254 nm) portable u.v. 
lamp (Mineralight, UVS-54, ULTRA-VIOLET Products inc. U.S.A). For some 
synthesized compounds this method of visualisation was not successful, so 
another t.l.c. tank saturated with iodine vapour was used to locate these steroids.
The radioactivity profile on the plates were examined using a Berthold LB 
2842, Automatic TLC-Linear Analyser. The Carrier gas was argon/methane(90:10). 
When monitoring the immunoreactivity profiles of the synthesized compounds, the 
plates were marked out into the tracks and 1 cm sections along each track were 
scrapped away from the glass and collected into labelled Soveril tubes. The silica in 
each tube was extracted twice with an appropriate solvent and the combined solvent
was dried under nitrogen at 37°C and the residues in each case were resuspended in 
assay buffer before assay.
b) High Performance Liquid Chromatography (H.P.L.C)
The use of H.P.L.C was limited to the investigation of the purity of the 
synthesized steroids and studying the possibility of finding suitable conditions for 
separating 4-OHA from closely related compounds. The instrument used was a 
Waters fitted with a model 440 detector monitoring absorbance at 254 nm, a model 
6000 pump and a model U6K injector.
The following H.P.L.C conditions were used:
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Column: Hypersil ODS 0.50 x 25 cm
Pressure: 1500 psi
Sample size: 5-20 pi
Range: 0.05 AUFS
Flow Rate: 1 ml/min
Mobile Phase: acetonitrile:water:glacial acetic acid (65:35:2)
Chart speed: 5 mm/min
c) Lipidex 5000
This column packing material is a powerful medium for the separation of 
closely related steroids (Apter et al. 1976 and Janne et al. 1974). It is an alkoxy 
derivative of Sephadex LH-20 with approximately 50% substitution. The 
difference between Lipidex 5000 and the parent material Sephadex LH-20 is that 
Lipidex 50(X) combines both lipophilic and hydrophobic properties at the same 
time. The use of Lipidex 50(X) has been described for the separation of 4-OHA 
from AD by Dowsett et al (1987). The chromatography was carried out in 18-cm 
columns of Lipidex 5000 prepared in 2-ml disposable glass pipettes. The Lipidex 
5000 was provided from Packard in a methanol suspension to prolong its shelf life. 
This solvent was replaced with the eluting system by using a sintered glass funnel 
and a flask connected to a water pump. Before packing, the columns were washed 
with the eluting solvent. Long pasteur pipettes were used to load the packing 
material into the columns. These pasteur pipettes were also used to transfer the 
samples (75pl) onto the top of the Lipidex columns.
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Immunisation:
Steroid antisera have been produced in a wide variety of mammals. Although 
the majority of antisera have been produced in rabbits and sheep, other animals 
such as hamsters, rats, goats and Rhesus monkeys have also been successfully 
used. For most laboratories, maintenance of rabbits, is not much of a problem. 
Sheep, however, are more difficult although they have the advantage of offering 
large volumes of antiserum. Fortunately, facilities for using sheep, for the present 
work were available at the University of Surrey and so no other animal species was 
considered.
Immunisation Protocol
Many techniques for immunising animals have been described, mostly 
involving intra-dermal, sub-cutaneous or intra-muscular injection. The biological 
requirement is that as many lymph nodes as possible are stimulated by the antigen 
for as long as possible. The immunisation route used for this work was 
intra-muscular, and had been successfully used before for steroid and drug antisera 
production ( Brian Morris, personal comm.). The protocol used was the 
following: for the prime immunisation, the steroid conjugate (see chapter 3) (5mg) 
was dissolved in 1 ml of sterile physiological saline. BCG (0.2ml) and 2 ml of 
non-ulcerative Freund's complete adjuvant (Guildhay Antisera Ltd) were then 
added and the mixture was then emulsified together. This was achieved by the use 
of an adaptor to couple together two syringes and pumping the contents from one 
syringe to the other through the adapter. Approximately 3 ml of the stable emulsion 
was injected into the sheep using 2" needles (19G). The conjugates were injected at 
six intra-muscular sites (shoulders, thighs and loin, 0.5ml per site). Blood was 
taken by jugular venepuncture immediately prior to immunisation. Five sheep were 
injected, and the following table shows the type of conjugate injected into each 
sheep:
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Conjugate Sheen Code
4-OHT-17p-HS-ovalbumin 1512 + 1513
4-OHA-7 a-CET-ovalbumin 1514
4-0HA-7 a-CET-ovalbumin 1515 + A2
Sheep 1512,1513,1514 and 1515 were Suffolk crosses and sheep A2 was a Black 
Face. Blood sampling was started nine days after the primary immunisation.
Radioimmunoassay Protocol for 4-OHA:
a) Assay Buffer For 4-OHA RIA
The assay buffer was a 0.01 M phosphate buffer pH 7.4, and was used within 
three weeks of preparation. The buffer contained the following:
NaCl 8.8 g
NaH2P04.2H20 0.3 g
Na2P04 1.15 g
thiomersal 0.2 g
gelatin 1 g
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These except gelatin, were dissolved in 950 ml of glass distilled water. The pH 
of the solution was adjusted to 7.4 by the addition of few drops of sodium 
hydroxide (5 M) solution. The gelatin was dissolved separately in 50 ml of water
by applying heat (45 °C) and stirring at the same time. This was allowed to cool
before adding it to the buffer. The buffer was then well mixed and stored at 4 °C 
for a maximum period of three weeks.
b) Preparation of steroid standards
Standard solutions of 4-OHA, and all other steroids used during the work were 
prepared as follows:
1. Stock standard, 1 mg/ml in ethanol: 10 mg of 4-OHA were dissolved in 10 ml of 
absolute ethanol.
2. Intermediate solution of standard, 1 pg/ml ethanol. The stock standard was 
diluted 1:10 in absolute ethanol to give a solution of 1(X) pg/ml. An aliquot (0.1 ml) 
of this solution was diluted to 10 ml with absolute ethanol to give the 1 pg/ml
standard. Solutions 1 and 2 were stored at -20 °C to minimize evaporation (these 
were stable for at least 4 months).
3. Working standard solution, 100 ng/ml. 1 ml of the 1 pg/ml standard solution 
was diluted to 10 ml with assay buffer. This was normally consumed within a 
month.
4. Assay standard: for each run the working standard solution was diluted in assay 
buffer to give the following concentrations of steroid : 16, 32, 65, 125, 250, 500, 
1000,2000 and 4000 pg/ml.
c) Dextran-coated charcoal
Dextran-coated charcoal (2.5%) was prepared by mixing a suspension of Norit 
A and dextran T-70. Dextran T-70 (2.5 g) was suspended in 500 ml of assay 
buffer (without gelatin) by continuously stirring with a magnetic stirrer. A Norit A
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charcoal suspension (25g in 500 ml of assay buffer) was added and the stirring 
continued until well mixed. This solution was stored refrigerated for periods of up 
to three months,
d) Assay protocol
The final assay procedure was conducted as follows: antiserum (0.1 ml, 
appropriately diluted), and 0.1 ml of tritium-labelled 4-OHA (20 pg/tube, 20(X)cpm) 
were incubated with 0.1 ml of assay buffer and 0.1 ml of standard or plasma 
sample. The final incubation volume was 0.4 ml. In addition, total (t) and 
nonspecific binding tubes (NSB) were prepared by adding 0.1 ml of label and 0.4 
ml of buffer for the totals and 0.1 ml of label and 0.3 ml of buffer for the NSBs. 
The assay was always carried out in duplicate unless otherwise stated. All tubes
were vortex-mixed briefly and incubated overnight at 4 °C. Separation of the 
bound and unbound 4-OHA was achieved by the addition of 0.1 ml of ice cold 
dextran coated charcoal suspension, which was being mixed on a magnetic stirrer, 
to each tube except the totals. Tubes were then allowed to stand for 10-15 minutes
on ice followed by centifugation for 10 minutes at 2500 rev./min. at 4 °C. 
Supernatants (0.4 ml) were then transferred into scintillation vials, mixed with 4 ml 
of scintillation fluid (Optiphase'Safe', Pharmacia/LKB), and counted for five 
minutes or up to 10,000 cpm. The standard curve was plotted using a smoothed 
spline programme (LKB, Wallac 1217, ReckBeta) and concentrations of 4-OHA in 
each dilution of sample automatically calculated. The tubes used in this assay were 
plastic LP3 and not glass as there was no difference in the 4-OHA standard curve 
when both types of tubes were used in a same assay (see chapter 5). The assay 
protocol is summarized in Table. 1.
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Table 1 : Protocol For 4-OHA radioimmunoassay
Volume of reagents added (ull
Reagent (T1 (NSBl Standard tube
Assay buffer 400 300 200
Standard - - 100
Antiserum dilution - - 100
Label 100 100 100
Incubate overnight at 4 °C
Dextran-coated - 100 100
charcoal (2.5%)
Mix and incubate with DCC for 10 minutes at 4 °C, centrifuge 
at 2500 rev. for 10 minutes at 4 °C.
Transfer 0.4 ml of supernatant into scintillation vials.
Add 4 ,ml of scintillation fluid "Optiphase"
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Calculation of Equilibrium constants:
An equilibrium constant ( K )  is an expression of the reaction energy of an assay. 
It gives information about the binding affinities of an antiserum under a particular 
set of conditions. As the specific activity of the label was known (p97), the mass 
of 4-OHA as label could be estimated. Knowing this, the total mass of 4-OHA 
added for each point on the standard curve could be calculated. Using the values of 
percentage radioactivity bound, obtained from the standard curve, the mass of 
4-OHA, bound and free, can be obtained. The equilibrium constant can then be 
calculated from the ligand form of the Scatchard equation (Frankel; 1981) as shown 
below:
[Aglbound/ [Aglft-ee — “Rs[Ag]bound ^R[Ab]jQjgj
where n is the valence of the antibody (Ab) and s is the valence of the antigen 
(Ag). So for univalent antigens this equation becomes:
[AgJbound /  [Aglfree ~  “RfAglboimd ^K[Ab]^Qjg|
A plot of [Aglbound / [Aglfree V S  [AgJbond will have a slope of - K  ,
Extraction Procedure:
Patient and animal samples (volumes depended on the expected drug 
concentration) were diluted up to 0.4 ml with de-ionised water. Five volumes of 
extraction solvents (diethylether:dichloromethane, 4:1, v/v) were added to the 
extraction tubes twice. Each of the tubes was mixed vigorously for two minutes
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before it was left for 30 minutes on a bench rotary mixer. The extracts of each 
sample were pooled, evaporated to dryness under nitrogen and the residue 
redissolved in assay buffer (0.5ml). Another aliquot of the neat sample was taken 
when comparison was to be made between direct and ’extract’ RIA.
RIA of 4-OHA using AD antiserum
The initial work in this project was carried out using antiserum to AD. The 
structure of AD is very closely related to that of 4-OHA and, in fact, is used as a 
precursor for its chemical synthesis. In addition to that, AD is cheaply and readily 
available. AD was used first as a starting material for the preparation of 4-OHA as 
described later in this chapter. The possibility of 4-OHA crossreacting with tha AD 
antiserum was also investigated. The antiserum used was obtained fiom Guildhay 
Antisera Ltd (HP/S/665-1A) which was raised in a sheep against the conjugate: 
androstenedione-7a-carboxyethylthioether-7a-ovalbumin. The assay buffer used 
to conduct this study was: phosphate saline, O.IM, pH 6.7, and contained 0.1% 
gelatin and sodium azide as preservative. The bound and free steroids were 
separated using a charcoal suspension (0.7%). A stock solution was prepared in 
benzene:ethanol (9:1) containing 50 pCi/ml and was used to make the working 
solution of 1 nmol/L. The range of AD concentrations used to construct the 
standard curve was between 0.125 to 7 pmol/ml and for 4-OHA, was between 
0.125 to 50 pmol/ml. A significant cross-reactivity between 4-OHA and the AD 
antiserum was found, ranging between 25-50% depending on the antiserum batch. 
Since this work was undertaken, Dowsett et al (19871 reported an RIA method for 
the measurement of 4-OHA which made use of AD antiserum. The cross-reactivity 
obtained in the present study for one batch of antiserum is shown in Fig. 11.
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CMAFTEH THEEE
CHEMICAL SYNTHESIS
Preparation of 4-Hydroxy-4-androstene-3,17-dione
The isolation of 4-OHA as a minor product of synthesis of 2-hydroxy-steioid 
4-en-3-ones was originally reported by Burnett et al (1973). The method used for 
the chemical synthesis of this compound for the present work was that of Tomoeda 
et al (1965) with the modification of Brodie et al (1977). This preparation was 
carried out before 4-OHA was commercially available in sufficient quantity.
a)- Epoxidation of Androstenedione
AD (500mg) was dissolved in cold methanol (20ml). To this, aqueous solutions 
of hydrogen peroxide (30%;v/v, 1.7ml) and sodium hydroxide (2%, 0.9ml) were 
added slowly with stirring. The stirring continued for 20 minutes, the reaction
mixture was allowed to stand overnight at 4 °Cand then the mixture was poured 
onto ice-cold water (30ml). This produced a precipitate which was filtered and 
washed well with water before drying under reduced pressure (weight 325mg).
A sample was checked for homogeneity by silica gel t.l.c. using the system 
benzenerethylacetate (85:15) using reference samples of AD (Sigma) and 4-OHA 
(Ciba-Geigy) . The product showed, under u.v lamp (254nm), one zone
corresponding to the reference spot of 4-OHA (Rf:0.38) but none with the Rf value 
of AD. However a major spot did appear after exposure to iodine vapour and had 
the Rf value of 0.16 which corresponded to the Rf value quoted by Brodie et al 
(1977) for the epoxide. The fact that no spot was observed in the place of AD 
suggested that the reaction was complete. The minor spot which was seen under
u.v and was similar in Rf value to the 4-OHA reference spot indicated a partial 
conversion to 4-OHA at this stage of the reaction. The yield of the epoxide was 
65% .
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b)- Preparation of 4-OHA
The dry epoxide was transferred in portions into a flask of concentrated sulfuric 
acid in glacial acetic acid (2%, 10ml). The reaction mixture was left in a shaking
water bath at 20 °C for approximately 3 hours; then it was poured onto crushed ice
(60ml) and allowed to stand overnight at 4 °C. The mixture was filtered and the 
precipitate washed three times with cold water before drying in a desiccator. The 
chemical pathway for the synthesis of 4-OHA from AD is shown in Fig. 12.
A sample was checked by silica gel t.l.c. using the system benzenerethylacetate 
(95:5) and it showed that the product was not homogeneous. A major zone did
appear at Rf 0.38 which had the same chromatographic mobility as a reference
sample of 4-OHA. Two other by-products, in trace amounts, appeared at Rfg values
0.10 and 0.20. AD had an Rf value of 0.20 in this solvent system. The Rfg values 
of AD, AD epoxide and 4-OHA on t.l.c with the solvent systems 
benzenerethylacetate (85:15, V/V) and benzenermethanol (95:5, v/v) are given in 
table 2. The overall yield of 4-OHA was 15% .
Table 2: Rf values of AD, AD epoxide and 4-OHA on silica gel t l .c .
Steroid Rfi Rf2 Rf relative to AD
(D* (2)*
AD 0.20 0.30 1 1
AD epoxide 0.18 0.25 0.9 0.83
4-OHA 0.38 0.48 1.9 1.6
* Rff obtained with system 1 benzenerethylacetate (85:15, v/v), and Rf  ^ with 
system 2 benzenermethanol (95:5).
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AD
AD EPOXIDE
OH 4-OH A
FIG. 12: Chemical synthesis of 4-OHA.
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Preparation of 4-hydroxy-testosterone
The synthesis of this compound was undertaken for two reasons: firstly, the 
possibility of using 4-OHT as a starting material in the preparation of the drug 
conjugates at position C-17 which could be achieved via a hemisuccinate bridge at 
position C-17 and secondly 4-OHT is not available commercially.
a)- Epoxidation of testosterone
Testosterone (500mg) was dissolved in methanol (20ml) and cooled down to 0
°C,then treated, while stirring, with ice-cold aqueous solution of hydrogen 
peroxide (30%, 1.7ml) and sodium hydroxide (2%, 0.9ml). The stirring continued
for 30 minutes, then the reaction mixture allowed to stand at 5 °C overnight. The 
reaction mixture was poured into vigorously stirred iced-water (70ml); this 
produced a fine white precipitate immediately. After 15 minutes, the mixture was 
filtered and the precipitate was collected and dried under reduced pressure.
A sample was checked by silica gel t.l.c. for homogeneity using the system 
chloroform:ethylacetate (90:10, v/v). A zone was detected under u.v light at 254nm
with Rf value of 0.23. The reference T sample was detected at Rf value of 0.21 
which although not clearly separated from the epoxide was nevertheless 
distinguishable. The product weighed 325mg and the yield of T epoxide from T 
was 65% .
b)- Hydroxylation of T epoxide
Testosterone epoxide (300mg) was dissolved in a cooled solution of glacial 
acetic acid (8ml) and concentrated sulphuric acid (170ml). The reaction mixture was 
warmed to room temperature and allowed to stand for about 2.5 hours. Then, the 
mixture was poured onto crushed ice (l(X)ml) and allowed to stand for 50 minutes 
before filtration and drying. The product had a veiy fine precipitate appearance.
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The yield of the product from the epoxide was 70% (210mg). The overall yield 
of the crude 4-OHT from T was 42% .
The proposed route for this reaction is shown in Fig. 13.
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OH
T
OH
T EPOXIDE
OH
OH
Fig. 13: Chemical synthesis of 4-OHT.
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Characterisation of the products synthesized: 
4-Hydroxy-androstenedione
i) All 4-hydroxy-3-keto-steroids give a dark green colour when reacted with ferric 
chloride in aqueous ethanol (Camrino et al..19611 A positive reaction with ferric 
chloride was obtained for this product.
ii) Identification of one major zone under u.v light after application of a sample of 
the product on silica gel t.l.c using the system benzenermethanol (95:5, v/v ). This
zone had an Rf value similar to that obtained from a pure reference sample of
4-OHA (Ciba-Geigy).
iii) Disappearance of the absorption band at 243 nm, the absorption maxima of AD, 
implying the conversion of all the AD in the reaction.
iv) U.V spectrum of a methanol solution of the product revealed the presence of 
absorption band at 278 nm, the absorption maxima of 4-OHA, implying insertion 
of a hydroxyl group at position C-4 of the steroid.
4-Hydroxy-testosterone
i) A positive reaction with ferric chloride was obtained.
ii) U.V spectrum of the product revealed the presence of an absorption band at 
278 nm, implying the synthesis of 4-hydroxyl group and disappearance of the 
absorption band at 243 nm (the absorption maxima of testosterone and testosterone 
epoxide). This is shown in Fig. 14.
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iii) Mass spectra: the mass spectrum of the product revealed an apparent peak of 
M+304 which is the molecular weight of 4-OHT. According to Foster et al (1986), 
the mass spectrum of 4-OHT is distinguished by a very prominent fragment ion at 
m/z 147, which is the base peak in the spectrum of 4-OHA and presumably, 
incorporating the unmodified ring A. The data obtained here agree with that. Also 
the spectrum profile of the product shows the following:
M+-2= m/z 302 (loss of hydrogen)
M+-(18+18)= m/z 268 (loss of 2XH2O)
M+-18= m/z 286 (loss of H2O)
The mass spectra of the product 4-OHT is shown in Fig. 15.
iv) Application of a sample of the product on a t.l.c plate using the system 
chloroform:ethylacetate (90:10, v/v) showed one major zone under u.v light. This
zone had an Rf value of 0.76.
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Fig. 14: U.V spectrum of T and 4-OHT*
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* This compound was synthesized in the laboratoiy.
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Fig. 15: The mass spectrum of the product 4-OHT.
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Preparation of 4-hydroxy-testosterone-17p-hemisu- 
ccinate (4-OHTHS)
The preparation of the above compound was carried out by hydroxylating the 
commercially available testosterone-17p-hemisuccinate (THS) at the C-4 position.
The idea of preparing this compound was to try and use it for the preparation of 
a conjugate of 4-OHA which could be linked to a protein at the C-17 position.
a)- Epoxidation of THS
The reaction used here was a modification of the reaction used in previous 
steroids epoxidations (Henbest et al 1977).
Testosterone-17p-hemisuccinate (THS, Grade 1, 500mg) was dissolved in
methanol (AR, 20ml) and the mixture was cooled down to about 0°C. While 
stirring, the solution was treated with an aqueous solution of hydrogen peroxide 
(30%, 1.7ml) and sodium hydroxide (20%, 1ml). The alkalinity of the sodium 
hydroxide in this reaction was raised from 2% to 20% . This was found to be 
necessary if a complete reaction was to be achieved.
The stirring continued for an additional 30 minutes, then the reaction mixture
was allowed to stand overnight at 4°C. The following moming,the reaction mixture 
was acidified to pH 4.5 by the addition of HCl (3M). The acidified mixture was 
then poured onto a magnetically stirred ice-bath water (110ml). The cloudy mixture 
was extracted with ethylacetate (5 volumes) and the organic phase was evaporated
to dryness at 45°C.
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The residue , which had the appearance of a dense gummy layer, was dried 
under reduced pressure to give light white crystals (350mg). The yield of 
THS-epoxide from THS was 70% .
b)- Preparation of 4-OHTHS
A cooled mixture of sulphuric acid and glacial acetic acid (2:98, v/v, 9ml) was 
added to the epoxide (3(X)mg). The reaction mixture then was allowed to proceed 
for 2.5 hours at room temperature with occasional shaking, after which the reaction 
mixture was poured into iced-water (90ml) with continuous stirring. The stirring 
continued for 30 minutes before filtration. The precipitate was collected (150mg) 
and washed well with water, then dried under reduced pressure.
The yield of 4-OHTHS from THS-epoxide was 50% and the overall yield of 
4-OHTHS from THS was 30% . Fig. 16 shows the chemical modification of 
THS.
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THS
0 —C—CHj—CHj—COOH
C H z—CH z— COOH
THS EPOXIDE
0 _ C  _ C H  2_C H  2 _ C 0 0 H
OH
Fig. 16: The chemical modification of THS.
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Characterisation of 4-OHTHS
i) The product gave a dark green colour with ferric chloride thereby indicating 
the presence of 3-keto-4-ene-4-hydroxy group in the product.
ii) U.V spectrum of the product revealed the disappearance of the absorption 
band at 243 nm of THS, and the appearance of a new absorption band at 278 nm, 
the characteristic band of 4-OH compounds as shown in Fig. 17.
iii) Mass spectrum profile of the 4-OHTHS revealed (Fig. 18):
M+ 404 = the molecular weight of 4-OHTHS. 
m/z 304 = loss of succinic anhydride.
m/z 286 = loss of H2O. 
m/z 268 = loss of two H2O.
Also shown in the mass spectrum is the prominent fragment ion at m/z 147, 
indicating the preservation of the ring A of the molecule (Foster etal.. 1986).
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Fig. 17: U.V spectrum of THS and its 4-hydroxy derivative.
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Preparation of the conjugate: 4 -O H T -17p-hem isuceinate-
17-ovalbum in
4-Hydroxyandrostenedione is a small molecule (mol. wt 302), hence is unlikely 
to invoke the immune response by itself. It must, therefore be linked covalently to a 
macromolecule, e.g.ovalbumin, to render it antigenic.
The mixed anhydride procedures (Erlanger etal 1957) were used to prepare the 
steroid-protein conjugates. The reaction was carried out in two stages as illustrated 
in Fig. 19. Stage one, relates to the formation of the mixed acid anhydride and 
must be carried out under anhydrous conditions. Stage two, the acid anhydride is 
decomposed by the e-amino groups of lysine residues in the carrier protein. Water 
must be present in the second stage to effect hydrolysis and because the protein can 
not be dissolved in anhydrous solvents (Kellie et al. 1975).
Conjugation
Solution A : The steroid hemisuccinate 4-OHTHS (25mg) was dissolved in 0.5 
ml of dry distilled dioxane [ 'Analar' kept over KOH pellets in a dark bottle] in a 
glass tube with a glass stopper. Tri-n-butylamine (28.5 pi), kept over KOH pellets 
in a dark bottle, was added to it with continuous stirring. The temperature was
brought down to 10 °C, after which iso-butyl-chloroformate (7.8 pi) was added 
while the stirring continued. The reaction was allowed to proceed for 40 minutes at
10 °C for the formation of the mixed anhydride products.
Solution B : while the reaction in step 1 was in progress, ovalbumin (100 mg) 
was added in portions to magnetically stirred glass distilled water (2 ml) in a
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separate glass bottle, and the solution was cooled down to 4 °C. Five minutes 
before the end of the reaction period of solution A, sodium hydroxide solution (0.1 
ml, IM) was added and the solution became clear while fast stirring was applied. 
Then, 2 ml of dry distilled 1,4 dioxane was added dropwise during stirring and the 
solution became clear.
Combination of A and B: solution A was added very slowly and carefully to 
solution B while the latter was stirred in iced-water. At this point solution B turned
cloudy. The combined solutions were left then at 4 °C for about 3.5 hours 
applying mild stirring.
The pH of the reaction mixture was kept between 8.5-9 by the addition of 
NaOH (IM) when necessary. After 40 minutes, the major part of the reaction was 
complete as indicated by the relatively fixed pH.
Dialysis: the reaction mixture was dialysed against distilled water (2 x 4 L) at 4
°C over 48 hours. The dialysis tubing (Visking tube 8/32") was then emptied into a 
beaker, diluted to 50 ml with de-ionised water and mixed before dividing it into 2 
ml portions containing approx. 4 mg protein, the products were lyophilised and
stored at 4 °C. This conjugate was injected into sheep code-numbered 1512 and 
1513.
Fig. 19 illustrates the two stages of the mixed anhydride procedure which was 
used for conjugating both 4-OHTHS and 4-OHA-7a-CET to protein.
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STAGE 1
O -C -C jH s-C O O H
+ RO*COCl + tri  -  n - b u t y  l ü m i n e
OH
O -C O -C H 2-C H 2
>L I
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ROHcl
OH
STAGE 2
p - C O —CH;—CH
'  I ' 
c = o
À
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+ R. NH:  ( ( - a mi n o  g r o u p )
O—CO—CH;—CH 2—CO
NH
ovalbumin
OH
Fig.l9: The conjugation of 4-OHTHS to protein.
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Preparation of the conjugate: 4-OHA-7a-carboxy- 
ethylthioether-7a-ovalbumin
In the first immunogen, the drug was conjugated at the C-17 position . The 
reason of selecting such sites on the drug is to ensure the preservation of the A ring 
of the drug which contains the important hydroxyl group at the C-4 position. The 
A ring of 4-OHA would be expected to be a major antigenic determinant in the 
process of producing specific antibodies to the drug; so leaving it free and fully 
exposed could be rewarding when a veiy specific antiserum is required.
Against this background the C-7 position of the drug was also selected for the 
preparation of the second immunogen, 4 - O H A - 7 a - c a r b o x y  
ethylthioether-7a-ovalbumin (4-OHA-7a-CET-7a-ovalbumin). This immunogen 
was prepared in a series of chemical reactions (Fig.20) and purification starting 
from the steroid AD which was converted into 4-hydroxy-androsta-4,6-diene-3,17-
dione (4-OH A^ *^ a). Then the 7a-carboxyethylthioether of 4-OHA was prepared 
by the use of a bifunctional reagent which contained an SH-group and a carboxyl 
group. The SH-group performed the neucleophilic attack on the C-7 of the drug, 
whereas the carboxyl group ensured the formation of the peptide bond with the 
lysine residue of the protein (Weinstein etal.. 1972).
This immunogen should have two distinctive advantages over the previous one 
(i.e.4-OHT-17p-HS-17-ovalbumin): (a)- Unlike the previous conjugate, this 
immunogen would have the keto group at C-17 position intact which might act as 
an additional epitope together with the 4-OH and 3-keto groups, (b)- It is believed 
that position 7 of the steroids in general is the least likely to be subject to any 
peripheral metabolism (Pratt, 1978).
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Fig.20: The preparation of 4-OHA-7a-CET-ovalbumin.
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Preparation  of 4-OH-androst-4,6-diene-3,17-dione
The method which was used to prepare this compound was that of March et al 
(1982) with minor modification.
A fteshly prepared solution of potassium-t-butoxide (2.57g) in t-butanol (30ml) 
was added very slowly with stirring to AD (2g) in t-butanol (80ml). The course of 
the reaction was followed by checking a sample by t.l.c and was terminated when a 
trace or no starting material appeared to be left unreacted. This took approximately 
20 hours. The t.l.c profile of the product was as shown in the following table:
Steroid Revalue
AD (ref.) 0.66
4-OHA (ref.) 0.82
4-OH A"*'^ A (product) 0.82 and 0.62
(solvent system: benzene/ethylacetate, 1:1, \/v)
It was presumed that all the AD was reacted in the reaction as no trace spot
corresponding to AD was detected. However, in addition to 4-OH A, a minor 
component was also found to be present. This substance had an Rf value of 0.62 
which was not AD , but it was more likely to be androstene-3,6,17-trione which
70 C hapter 3
was quoted to have an Revalue of 0.62 under the same conditions (March et al 
1982).
The reaction mixture was then acidified to pH 6 by the addition of glacial acetic
acid (10ml) and the butanol was removed by evaporation at 40 °C. The residuewas 
dissolved in a mixture of equal ratio of acetone and methanol (30ml), after which 
ether (250ml) was added to precipitate potassium acetate.Then the mixture was 
filtered and the filtrate concentrated. The remaining liquid was then poured into an 
ice-cold water (280ml); after filtration, the product was collected and dried in a 
desiccator.
A sample of the product was checked for homogeneity by t.l.c using the system 
benzenerethylacetate (1:1, v/v) and was found to be a mixture of two compounds
with Rf values of 0.82 (major compund) and 0.62 (minor compund).
Purification of 4-OHA^  ^ A on silica gel column:
The yellow coloured product (300mg) was dissolved in a mixture of benzene 
and ethylacetate (5ml, 1:1), applied to a silica gel glass column (2x30cm) and 
eluted with benzene:ethylacetate (1:1). The collection of the compound was started 
with the beginning of the yellow coloured band and stopped when the coloured 
band ended.
The eluate collected was dried under reduced pressure and then characterised. 
The yield of 4-OHA '^^A from AD was 10% .
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Characterisation of 4-OHA^^A :
The following data confirmed that the product was pure and had an hydroxyl 
group at position 4 plus the additional double bond:
i) A positive reaction with ferric chloride.
ii) A sample of the product showed only one spot on the silica gel tl.c with Rf 
value of 0.82, in the system benzene:ethylacetate (1:1, v/v).
iii) HPLC of the product (Hypersil ODS, 25cmx5mm) revealed only one peak 
detected at 278nm.
iv) The data obtained fiom N.M.R supported the presence of the additional
double bond and the hydroxyl group (Fig.21).
v) The U.V spectrum of the product agreed with that obtained by March et al 
(1982), 318nm (Fig.22).
vi) The mass spectrum of the product showed an abundant parent peak
corresponding to the molecular weight of 4-OHA '^^A M+300 (Fig.23).
Preparation of 4-OHA-7a-CET
4-Hydroxy-4,6-androstenediene-3,17-dione (lOOmg) was dissolved in 
re-distilled 1,4-dioxane (1ml) and stirred for 72 hours in the presence of sodium 
methoxide (200mg) and mercaptopropionic acid (200 p.1) in distilled dioxane 
(1.5ml). Ice-cold water (12ml) was added to the reaction mixture, which was 
extracted with ethylacetate (2x4ml). The aqueous phase was acidified with HCl 
(10%) to pH 4. This turned the aqueous phase very cloudy. The mixture was left
overnight at 4 °C and theprecipitate filtered. The solid material was washed well 
with water before drying using an oil pump.
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Fig.22: The u.v spectrum of 4-0HA'*«^A synthesized in the laboratory.
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Characterisation of the product
i) Support of the formation of the 7-addition product was obtained from the 
disappearance of the characteristic diene absorption band at 318nm, and the 
appearance of the 4-hydroxy-3-keto-steroid absorption band at 286nm (Fig.24).
ii) The mass spectra of the product showed an abundant parent peak 
corresponding to the molecular weight of 4-OHA-7a-CET M+406 (Fig.25).
4.500_
S.GDO:
111 2.700 U
Ig  1.800 
<
.900
.000  " /
'T  I  'I  I > ^  1 1  I I I I I I I ^  1 1 1 1 1 1 1  1 1  1 1 1 I H  1 1 1 1 I 1 1  I I I  I I I T 7  r i  T T -y 1 1  I  I ]  1 1 I I I  I I i  r ;  1 1  i  r  ]
210 220 230 240 250 260 270 280 290 900 810 820 890 340 850
nm
Wave I e n g t h
Fig.24: U.V spectrum of 4-OHA-7a-CET.
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Preparation of the second immunogen:
4-O H A -7a-C E T -7a-ovalbum in
The mixed anhydride method described earlier was used again to link the hapten 
derivative to ovalbumin. The conjugation method was similar to that described for 
4-OHTHS with minor differences.
Solution A: 4-OHA-7a-CET (25 mg) was dissolved first in dimethyl sulfoxide 
(DMSO, 150 pi) in a small glass bottle and then dioxane (350 pi) was added. The 
presence of DMSO in this mixture was necessary as 4-OHA-7a-CET did not 
dissolve in dioxane alone. Tri-n-butylamine (28.5 pi) was added with mixing 
before the small bottle was covered with glass stopper and the solution cooled to 10
°C. After that iso-butylchloroformate (7.8 pi) was added quickly under the surface 
of the reaction mixture and mixed. The reaction was then allowed to proceed for 40
minutes at 10 °C.
Solution B: ovalbumin (100 mg) was added in portions to de-ionized water (2 
ml) in a small glass tube during stirring and then the solution was cooled downto 4 
°C. Five minutes before the reaction in solution A was about to finish, sodium 
hydroxide (IM, 100 pi) was added to solution B with stirring. This clarified the 
cloudy solution and then dry dioxane (2 ml) was added slowly to the mixture 
which caused the solution to be even clearer. Solution A was added very slowly 
and carefully to
solution B which was maintained at 4°C withvigorous stirring. The reaction 
mixture which became cloudy at this point wsa left for four hours at 4 °C.
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The pH of the reaction was maintained between 8.5-9 by the occasional addition 
of NaOH (IM) when necessary. After that, the reaction mixture was transferred to 
dialysis tubing. The dialysis was carried out against two successive changes of 
distilled water at 4 °C (2x2L) for two days. The contents of the tubing was then 
diluted to 50 ml with water and then divided into 25 parts to give 4 mg conjugate 
per vial. The vials were then kept at -30 °C for 24 hours before freeze-drying.
The characterisation of the products described are summarised in table 3.
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Table 3: The characterisation of the sythesized compounds.
Product
synthesized
Characterisation
a) Positive reaction with FeCl.
b) The mass spectra revealed apparent peak of M+304. 
4-OHT c) One major spot in a silica gel Ll.c with Rj0.76 using the
system chloroformrethylacetate (90:10). 
d) U.V. spectrum revealed the presence of absorption band at 
278 nm implying the introduction of 4-hydroxyl group.
a) Positive reaction with FeCl.
b) On a silica gel t.l.c. a major spot was detected under U.V. 
lamp at Rf 0.16. A reference sample of THS had Rf of 0.12.
4-OHTHS c) U.V. spectrum revealed the presence of absorption band 
at 278 nm, the characteristic band of 4-OH compounds,
d) High performence liquid chromatography of a sample gave 
one peak detected at 278nm.
a) The product showed only one spot on silica gel t.l.c.
b) Positive reaction with ferric chloride.
c) N.M.R. data supported the presence of the additional double
4-OHA^’^ A band and the hydroxyl group.
d) the mass spectra of the product showed an abundant parent peak
corresponding to the molecular weight of 4-0HA"**^A (M+300).
e) The U.V. spectrum agreed with that obtained by March etal 
(1982)max318.
a) Support for the formation of the 7 -addition product was 
obtained from the disappearance of the characteristicdiene 
absorption band at 318 nm and the appearance of the OH-3-keto 
steroid absorption band at 286 nm.4-OHA-7a-
CET
b) The mass spectra of the product showed an abundant parent peak 
corresponding to the molecular weight of 4-OHA-7a-CET 
M+406.
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Synthesis of the Radio-labelled 4-OHA
The availability of a radioactive form of 4-OHA is of great importance, not only 
because it is vital in the development of the RIA of the drug, but also because of its 
potential use in the study of the drug metabolism and mechanism of action in 
animals.
There has been a lot of discussion about the relative merit of tritium (^H) and 
iodine in radioimmunoassay for steroids ( Allen and Redshaw; 1978 ). 
Tritium-labelled steroids are immunoreactively "identical" with the unlabelled 
steroids, thus their binding energies to the specific antibody are "identical". The 
same is not true for as this cannot generally be incorporated directly into the 
steroid molecule without destroying its immunoreactivity. To circumvent this, the 
steroid is conjugated to an aromatic moity, such as histamine, tyrosine...etc that can 
be iodinated. This may lead to different binding energies of the tracer and the cold 
drug toward the antibody (loss of immunoreactivity) and subsequently to a loss in 
assay sensitivity.
Tritium-labelled 4-OHA has been synthesized by March et al (1982) using the
starting material 4-0HA'^*^A. The latter compound was synthesized during the 
course of this work as a precursor for the preparation of the second immunogen, ( 
4-OHA-7a-CET-7a-ovabumin ). It was therefore decided to prepare the 
tritium-labelled drug while keeping the option open for changing to ^^I-labelling 
or a non-isotopic label if it was found to be necessary.
81 C hapter 3
Synthesis of 6,(7)-Tritio-4-hy(iroxy-4-ene-3,17-dione
The starting material for this synthesis was 4-OHA '^^A which was prepared as 
described previously in this chapter. The incorporation of tritium into the diene 
was carried out by Prof. J.Jones of the Department of Chemistry, University of 
Surrey. The method was that of March (1982).
Under high vacuum, 1.2ml of tritium ( measured at S.T.P. ) was added to 15
mg of 4-0HA"^’^ A (Fig.26) and 7.5 mg of 10% Pd/c in 1.5 ml of dioxane cooled 
in liquid nitrogen.
After warming to room temperature, the mixture was shaken (under vacuum) 
for 2 hours, then filtered and evaporated. The residue was then dissolved in 200 ml 
of toluenerethanol (9:1). The radioactivity concentration was Imci/lml, with 
specific activity of 16.6 Ci/mmol.
Purification of3H -4-0H A
Figs. 27 and 28 show the radioactivity profile of the tritiated 4-OHA before and 
after purification on both silica gel and Lipidex 5000 chromatography columns.
Purification on silica gel
This purification was carried out on small Pasteur pipette (0.7x9 cm) columns. 
The column was packed with silica gel (Kieselgel 60, 70-230 mesh ASTM ) 
blocked with glass wool, and the system used for elution was benzene:ethylacetate 
(1:1). A preliminary run with a mixture of the crude label and cold 4-OHA was 
carried out to establish the elution pattern of the drug. Fractions of 150 p.1 
were collected and two aliquots of each fraction were taken for both monitoring the
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radioactivity, and for screening chemically (ferric chloride test) for the presence of 
4-OHA . Fig.27 shows the radioactivity profile of the crude labelled drug after 
elution from the silica gel column using the system benzeneiethylacetatae (1:1); 
fractions 15 to 17 showed the highest radioactivity. Elution of radioactivity and 
4-OHA in these fractions paralleled each other.
A proper purification of the cmde label of 4-OHA was then carried out for the 
puipose of use in the RIA. A sample of the original label-material (0.1 ml, 0.1 mci) 
was dried under air and then redissolved in 50 pi of column eluant 
benzene:ethylacetate (1:1), and applied into a silical gel column (0.7x9cm). The 
column was washed first with the eluting system. Fractions between 2.2 and 2.7 
ml were collected, dried under air at 37 °C and then redissolved in toluene:ethanol 
(9:1) for storing at -20 °C. A sample of the purified label was applied onto silica 
t.l.c. plate to assess the purity; the developing system used was hexane:ether 
(80:20). Fig. 28 shows the radioactivity profile obtained after scanning the plate 
using a Berthold radioscanner.
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Fig.26: Synthesis of the tritiated 4-OHA.
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Fig.27: Elution profile of the crude ^H-4-OHA on silica gel column.
85 C hapter 3
Purification on Lipidex 5000
Lipidex 5000 is an effective material (Janne et al.19741 for the separation of 
the closely related steroids. The purification of the 3H-4-OHA on Lipidex 5000 
was carried out after its successful use for the separation of steroids in patient 
samples (Dowsett et al. 19871. Eighteen cm columns of Lipidex 5000 in 2 ml 
disposable glass pipettes (2ml) were used. The system used for the elution was 
trimethyl-pentanetisopropanol (1:5). The Lipidex 50(X) was provided by Packard in 
a methanol suspension to prolong its shelf life. This solvent was replaced with the 
elution system, trimethylpentanerisopropanol (1:5), by using a sintered glass funnel 
and a flask connected to water pump. Preliminary runs were carried out separately 
using the cold drug and the impure label (Fig. 29, a and b) to determine the location 
of 4-OHA and the radioactivity profile of the crude label. The cold drug was 
monitored by RIA of fractions collected from the column using the above 
mentioned silica-purified label, and the radioactivity eluted from the other column 
was monitored by counting the cpm in each fi-action collected.
Approximately 0.1 mCi of the crude 3H-4-OHA was applied in 75 pi of 
trimethylpentane:isopropanol (1:5) to a column of Lipidex packed similarly to the 
previous columns. Fractions between 3.25ml and 3.75ml were collected, dried 
under an air pump, and re-dissolved in ethanol for storage at -20 °C. A sample of 
the purified fraction was re-applied to a column of Lipidex 5000 to examine its 
purity, fractions of 0.25ml were collected and counted for radioactivity (Fig.29). 
The purity achieved was 95%.
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Fig.28: Radioactivity profile of 3H-40HA on Ll.c. plate.
(a) before (b) after purification, (sys. hexrether, 8:2, v/v)
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Fig. 29; Location of 4-OHA as determined by RIA (a). Elution profile of the 
tritiated 4-OHA on Lipidex column: as crude (b) and after purification 
on Lipidex (C)
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CHAPTER FOUR
Development of an RIA for the 
measurement of 4-OHA
Immune response in the sheep
The antisera produced were screened using the assay protocol described i.e with 
tritiated 4-OHA.
Only one sheep (1514), out of five, failed to show any response. The other 
sheep responded to various degrees. The reason for the failure of response in 
sheep 1514 was possibly related to the nature of the conjugate injected. This was 
prepared on a separate occasion from the batch of immunogen used to immunise the 
other animals. The immune response was monitored by evaluating the titre, which 
is defined as that dilution of the antiserum which binds 50% of maximum binding 
of label, and was performed by incubating various dilutions of the antiserum with a 
fixed mass of tritiated 4-OHA (20pg), in a fixed volume of a buffer, overnight at 4 
OC. One hundred days following the priming, there was still some increase in 
antibody production in sheep 1512, 1513 and A2. The plan was not to boost the 
animals until the concentration of ciculating antibodies had started to fall or reached 
a steady level. Table 4 illustrates the time course of boosts given to the sheep and 
Fig. 30 shows the initial response in all sheep after the primary immunisation and 
first boost.
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Table 4. The time course of boosts given to the sheep
Weeks from priming
Boost
First Second Third
13 1514,1515
22 1512, A2 1515
35 1513
52 1512
56 1513 1515
74 1512,1513
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In Fig. 30 a sharp increase in the immune response of sheep 1515, nine days 
after the first boost and one hundred days after priming , can be observed. Sheep 
1514 failed to generate any response after the first boost and it was,therefore, 
decided to discard this sheep and concentrate on the responders. Twenty two weeks 
(154 days) after the prime, the first boost was given to sheep 1512 and A2 and at 
the same time a second boost was given to sheep 1515 . The results of these boosts 
are illustrated in Fig. 31 where a huge increase in the immune response was 
observed in sheep 1512 and A 2. The titre was increased from 1/0.2K to 1/9K for 
sheep 1512 and from less than 1/0.05K to 1/2.5K for sheep A2. This represents 
about 50 fold increase in the concentration of the antisera. The second boost in 
Sheep 1515 failed to achieve any higher titre than that obtained after the first boost.
The progress in the response of Sheep 1513 was closely monitored because its 
initial response was particularly encouraging and as mentioned above the boost is 
best given after a decrease or a steady level in the antibody concentration is achieved 
(personal communication. Dr W.Aheme). This is why the first boost was given 35 
weeks after the priming which is relatively longer than the other sheep. The delay 
in boosting was rewarded by the achievement of an increase in the immune 
response of more than 90 fold (from 1: 0. IK to 1: 9.2K) as illustrated in Fig. 32 
A further increase in the titre was obtained after the second boosting which was 
given 56 weeks after the priming or 21 weeks after the first boost (Fig. 32). The 
antibody produced from sheep 1513 was not only higher in quantity but also better 
in quality, as will be discussed later. The superior quality of antiserum 1513 was 
the reason behind its selection for the development of the assay.
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Assessment of 4-OHA antisera
The properties of these antisera were assessed by measuring the titre, avidity 
and specificity.
Titre: Antiserum dilution curves were used to determine the titre of the antisera. 
Fig. 33 shows the antiserum dilution curves of HP/S/1513 lA obtained after the 
first boost.
Avidity: avidity, which indicates the quality of an antiserum, is critical in terms of 
the potential performance of the assay. An indirect assessment of the avidity of 
4-OHA antisera was obtained by setting up antiserum displacement curves. These 
curves were obtained by incubating a set of tubes which contained identical reagents 
to those used to derive the antiserum dilution curves, except that an aliquot of 
4-OHA standard (0.5ng) was added to each tube in each curve. Fig. 34 is an 
example of a displacement curve obtained by adding 0.5 ng of 4-OHA to an 
antiserum HP/S/1513 lA dilution curve. The sigmoid curve obtained was well 
displaced to the left of the antiserum dilution curve reflecting indirectly the degree of 
the antiserum avidity.
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Fig. 32: The immune response of sheep 1513 after two boosts.
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Choice of label: preparation of a conjugate suitable for
c h e m i lu m in e s c e n c e  im m u n o a s s a y
Although 3h  label of 4-OHA was available for the development of an RIA, 
attempts were made to evaluate the use of a chemiluminescent assay while waiting 
for the production of suitable antisera. The feasibility of developing a 
chemiluminescence immunoassay (LIA) was also investigated.
Studies by Kohen et al (1979, 1980) and by Collins et al (1983) have shown 
that chemiluminescent markers can be a feasible alternative to radiolabeling. 
Chemiluminescence is a very similar phenomenon to fluorescence. Whereas the 
exciting energy in fluorescence is in the form of light, in chemiluminescence it is 
provided by a chemical reaction. The relative proportion of emitted light, is a 
measure of the efficiency of the reaction. The chemiluminescent reaction chosen 
(Fig.35 ) was the production of light from luminol or isoluminol in the presence of 
peroxidase. The photon efficiency is about 1% . The reaction requires a catalyst, 
such as peroxidase, and an alkaline pH.
Many techniques have been developed and used in luminescent immunoassay 
such as: immunoluminometric assay (Weeks et al.. 1983), immunoluminometric 
labelled second antibody (Brown et al.. 1987), solid phase antigen luminescence 
technique and what is called CELIA or chemiluminescence immunoassay which is 
identical to solid phase radioimmunoassay except the antigen is labelled with a 
luminescent compound instead of a radioactive marker. In the present attempt to 
develop a chemiluminescent assay system for 4-OHA, the Solid Phase Antigen 
Luminescence Technique ( SPALT ) was employed (Gadow et al.. 1984). The 
SPALT technique utilises a solid phase coated with antigen and a second antibody 
labelled with a luminescent compound.
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Fig. 35: Chemiluminescence reaction of luminol/isoluminol.
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Preparation of 4-OHT-17p-HS-thyroglobulin conjugate:
The method of Erlanger (1957) which was used for the preparation of 4-OHA 
immunogens was used again to link the steroid derivative 4-OHT-17p-hemisuccinat 
(4-OHTHS, 2.25mg) to thyroglobulin (75mg). The conjugate was left for 4 hours 
at 4 °C with gentle stirring before it was dialysed for two successive days against 2 
X 2.5 L of deionised water. Later, the contents (15ml) of the tubing were emptied 
into a beaker and stored at 4 °C with sodium azide as preservative. A sample taken 
from the water used for the dialysis revealed that no free steroid (as determined by 
u.v absorption) had escaped the conjugation, so a complete conjugation was 
assumed.
Assay protocol
Buffers: Two types of buffers were used : Sodium barbitone (0.07M, pH 
9.6) and phosphate buffered saline. The first buffer was used for coating the 
cuvettes and the second for washing and other dilutions. For the preparation of the 
phosphate buffer, the following amounts were added to 1 L of glass distilled water:
NaCl 9g
KH2PO4 0.4 g
Na2HP0 4 .12H20 2.9 g
KCl 0.2  g
Gelatin 1.0 g
Sodium azide 1.0 g
A stock solution of microperoxidase (1 mg/ml) was prepared in phosphate 
buffer and stored at 4 °C. The working solution of microperoxidase ( 3% of the 
stock) was prepared by adding 150 pi of the stock solution to 5 ml of glass distilled
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water. The working solution of hydrogen peroxide was 1% of the 30 vols bottle 
and was always prepared fresh in glass distilled water.
The protocol used to construct the assay is outlined in Fig. 36 . 
4-OHT-17p-HS-thyroglobulin (0.3 ml, at various concentrations) was used in 
barbitone buffer to coat the cuvettes for 24 or 48 hours. Then, the excess reagent 
was removed by aspiration and the cuvettes washed once with glass distilled water 
(1ml) and once with phosphate buffer (1ml). 0.1 ml of each of phosphate buffer 
and steroid standard was added for the construction of the standard curve and 0.2 
ml of phosphate buffer was added for the dilution curve. The first antibody to 
4-OHA was then added (0.1 ml) and the cuvettes were left for at least one hour to 
incubate at room temperature. The cuvettes were then washed a few times with 
water (1ml) and once with phosphate buffer before the luminescent labelled second 
antibody (0.3 ml) was added. The labelled second antibody was DEAE purified 
Donkey anti-sheep IgG labelled with N-(4-aminobutyl)'N-ethylisoluminol 
hemisuccinate (ABEI-H) and was prepared according to Gadow_gl_al.(1984). The 
dilution at which the second antibody should be carried out is arbitrary but should 
be added in excess (at least 1:500). After incubation for at least 90 minutes at room 
temperature, the cuvettes were washed well and sodium hydroxide (0.3 ml, 2M) 
was added to each cuvette and left to incubate for 1 hour at 60 °C. The cuvettes 
were cooled to room temperature and the chemical reaction was initiated by the 
automatic dispensing of the catalyst microperoxidase (0.15 ml) and hydrogen 
peroxide (21 pi) by the luminometer (LKB 1251) which measured the light intensity 
for 5 seconds. The peak height were printed out by the microprocessor.
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Fig.36. Diagram illustrating the procedures followed for antibody dilution and 
standard curves.
Coat cuvettes for 24h or 48h
Wash once with glass distilled water and 
once with phosphate buffer
Add the following reagents
Reagent NSB A/S dilution curve Std curve
Std 
PBSGT 
First A/S
300 pi
100 pi 
200 pi 
100 pi
100 pi 
100 pi
Incubate Ih at RT, then wash as before and add ABEI 
labelled second antibody (300 pi) to all cuvettes
Incubate at least 90m at RT then wash as before
Add NaOH (300 pi, 2M) to all cuvettes 
1 hour incubation at 60 °C
After cooling to RT. Add 150 pi microperoxidase and 21 pi H2O2 to initiate the 
chemical reaction in the luminometer
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R esults
Antiserum dilution curve: different coating concentrations were used 
(1.5-7.5ng steroid/ml) in order to select the best coating cuconcentration suitable for 
use to construct the standard curve. The first antiserum used was 1512 lA 
(Fig.37). Another attempt was carried out using the antiserum 1515 2B to see if a 
better curve could be obtained (Fig.38).
Displacement curves with 4-OHA: Fig. 39 shows the displacement obtained 
by 4-OHA at lOpg/tube. Two different antibodies to 4-OHA were used, 
HP/S/1512 IB (which was raised to 4-OHTHS-ovalbumin) and HP/S/1515 2B 
(raised to 4-OHA linked to protien at C-7).
Standard curve: Initial attempts to construct a standard curve were not 
successful and the lack of time prevented further optimisation of the standard curve. 
Fig. 40 shows an example of a standard curve.
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Fig. 38: Antiserum dilution curve using different coating concentration of the 
conjugate (A/S: 1515 2B)
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Fig. 39: Antiserum displacement curves.
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Fig. 40: An example of a standard curve for 4-OHA.
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Standard curve: use of tritiated 4-OHA
Fig. 41 illustrates the mean dose-response curve from seven successive assays 
(interassay), in each of which duplicate concentrations of standards were used. The 
range of the standard was between 16 to 4000 pg/ml. The curve was linear in the 
range between 50-1500 pg/ml.
Assay precision and sensitivity:
Precision is defined as the spread of replicate observations about the mean. It is 
expressed as the standard deviation (SD) or, more usefully, as the coefficient of 
variation (CV) which is defined as 100 X SD /  mean. These values were calculated 
from seven separate 4-OHA standard curves. The mean standard curve is shown in 
Fig. 41. The standard deviation values and coefficient of variation for each 
concentration point are given in Table 5. The range of coefficient variations at 
standard concentrations below lOOOpg/ml was less than 6% indicating the 
satisfactory stability and precision of the standard curve.
The sensitivity of the standard curve, based on 2 SD of the mean of 15 replicate 
tests of the zero standard was 25 pg/ml. The % bound/total of the assay ranged 
from 40 to 60% and the nonspecific binding was less than 4% .
Although sensitivity and detection limit are often used interchangeably, they 
describe different parameters. The sensitivity of an assay is a feature of the 
precision at zero analyte concentration and is defined as the lowest concentration 
that can be distinguished from zero. The limit of detection of an assay is equal to 
the sensitivity multiplied by the lowest volume of sample added. The average 50% 
intercept of the standard curve was 300 pg/ml.
109 C hapter 4
It is widely recommended that radioimmunoassays are optimized with reference 
to its 'precision profile' ( a plot of CV as ordinate versus dose as abscissa) (Ekins, 
1981). This facilitates the selection of maximum precision in the region of the 
dose-response curve that is of principle interest to the analyst. A precision profile 
for 4-OHA samdard curve was constructed over the range (16-4000 pg/ml) and is 
shown in Fig. 41 . The nadir of the profile represents the range of concentration at 
which maximum precision is obtained.
Table 5. Assay variation of the 4-OHA standard curve
4-OHA CONCENTRATION (pg/mll
16 32 63 125 250 500 1000 2000 4000
Mean
%B/BO 91 85 77 68 54 40 24 18 9
S.D 5.5 4.3 3.3 3 2.5 2.5 3 2 2
%C.V 6 5 4.3 4.4 4.6 6 12.5 11 22
n = 7
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Fig. 41: The mean of seven separate 4-OHA standard curves and the precision 
profile of the standard curve.
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Afînity constant (Ka) of the antisera
Antibody affinity is an important determinant of the sensitivity of 
immunoassays. It is an expression of the reaction energy of an assay . Several 
methods have been described for determination of the affinity constant (Ka) of 
antibodies, including equilibrium dialysis (Eisen and Karush, 1965), fluorescence 
quenching (Velick et al.. 1960), and fluorescence polarization (Dandlicker et al.. 
1965). These techniques were used to determine the affinity of the purified or 
partially purified antibodies. For the calculation of the Ka of 4-OHA antisera the 
method used here was described by Muller (1980) and the data required for the 
calculation are: the molar concentration of cold 4-OHA concentration giving 50% 
inhibition of label antigen- antibody binding, the molar concentration of 3H-4-OHA 
concentration in the assay and the amount of 3H-4-0HA bound by the antibodies in 
the absence of the cold 4-OHA. It is stated that :
at 50% binding K^ =
3[dt)-(Tt)]
I[ = Inhibitor (cold 4-OHA) concentration.
Tt = Total tracer concentration.
Taking all the data from the 4-OHA standard curve and applying the above equation 
the afiinity constant for the
4-OHA antisera 1513 lA and A2 lA were calculated and found to be: IX  10^
L/M and 1 X 10^ ® L/M respectively.
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The Ka values obtained using the method described were in agreement with the
values obtained using the computerised Scatchard calculation (Scatchard, 1949) 
which required the following data: incubation volume, maximum bound counts, 
non-specific bound counts, molecular weight of antigen and amount of label added 
per tube.
Specificity of the antisera
Specificity of an antiserum can be defined as the freedom from interference by 
substances other than the steroid intended to be measured and is the characteristic 
which ultimately determines its usefulness (Niswender et al.. 1975). The extent to 
which a given compound can interfere is often referred to as the cross-reaction. 
The specificity of 4-OHA antisera was investigated by carrying out cross-reaction 
studies with various synthetic and natural steroids. Cross-reactivity studies were 
carried out by preparing a series of standard curves. One was set up containing 
increasing concentrations of 4-OHA, and others of increasing concentrations of 
compounds which could possibly cross react. The method used for calculation of 
cross-reactivity was that of Abraham (1968). The anti-steroid to be tested directed 
against steroid (S), is incubated at a fixed temperature, with a fixed mass of 
radioactively labelled (*S). Taking arbitrarily the cross-reaction of steroid (S) as 
1(X)%, the percent cross-reaction of steroid (X) is calculated at 50% displacement of 
(*S). The percent cross-reaction of (X) equals:
mass of steroid (S) required to displace 50% of (S*)
----------------------------------------------------------------------    X  100
mass of steroid (X) required to displace 50% of (*S)
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The results of the cross-reactivity studies are presented in Table 6. These 
cross-reactivity curves were carried out using two antisera HP/S/1513 lA and 
HP/S/A2 1 A. Antiserum HP/S/1513 lA was produced using the drug conjugated 
at position 17 whereas antiserum HP/S/A2 lA  was raised against the drug 
conjugated to protein at position 7. The cross-reactivity investigation was not
g
limited to the major androgens, but was also extended to other s^ id s, which varied 
both in the distance of the functional groups from the conjugation site of the 
antibody and in the orientiation of the functional groups. The results show that 
antiserum HP/S/1513 lA was more specific than antiserum HP/S/A2 lA. It 
showed no significant cross-reactivity with either AD or T, the steroids most 
closely related to 4-OHA, but antiserum HP/S/A2 1A exhibited higher avidity to AD 
than to 4-OHA (130%). 4-OHT a putative metabolite of 4-OHA cross-reacted by 
60% with antisemm HP/S/1513 lA, but showed no cross-reactivity with antiserum 
HP/S/A2 lA . One important compound listed in the table is 
3p-hydroxy-5a-androstan-4,17-dione which has been isolated as a major metabolite 
of 4-OHA. This compound showed almost no cross-reactivity with HP/S/1513 1A 
but did cross-react with antiserum HP/S/A2 lA by 30% . Accordingly, the 
antiserum HP/S/1513 lA was selected for the development of the assay and for 
other studies. Figs. 42 and 43 give the crossreactivity of various steroids with 
both antisera.
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Table 6. Cross-reactivity of steroids with two 4-OHA Antisera
% Cross-reaction
Steroid_______________ ____________________
HP/S/1513 lA HP/S/A2 lA
4-OHA  --------------------- 100 100
AD------------------------------------ 0.9 130
Testosterone------------------------- 2.4 <3
4-OHT--------------------------------  60 <0.8
3-OH-5a-androstan-4,17-dione— 0.6 31
4 -OHE 2--------------- --------------- 0.5
4-OHEi— --------- ----------------- 0.3
Corticosterone----------------------- <0.1
Cortisone  ----------------------<0.1
Cortisol-------------------------------<0.1 <3
Oestradiol---------------------------- <3 <3
progesterone------------------------- 0.6 5.8
17a-OH-progesterone-------------- 0.5
Deoxy-corticosterone--------------- 0.5
Dehydroepiandrosterone (DHA)— <0.3
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Effect of neat plasma on the standard curve
In the development of direct immunoassays it is essential to show minimum or 
no effect from plasma matrix at the working dilutions of plasma samples on the 
assay standard curve. Direct use of specimens for assay not only are conducive to 
speedy analysis but may also limit errors introduced by extraction procedures.
The effects of plasma were investigated by adding up to 50 pi of normal female 
plasma to 4-OHA standard curves and comparing the curves obtained with 4-OHA 
standard curve carried out in assay buffer only. The results are shown in Fig. 44. 
The addition of 50 pi and 100 pi of neat plasma caused deviation from the buffer 
standard curve. However, the addition of less than 50 pi of plasma caused minimal 
alteration to the shape or 100% binding of the standard curve. Therefore, dilutions 
of plasma of greater than 1/4 could be used for direct sample analysis.
Intra- and interassay variations
The reproducibility of the assay was determined by intra- and interassay 
variations. For the intra- or within assay variation, different known amounts of 
authentic 4-OHA were added to normal female plasma. These amounts represented 
low, medium and high concentrations of the drug assayed at 2-3 dilutions in 
duplicate. Almost complete recovery was obtained as shown in Table 7 reflecting 
good accuracy with a coefficent of variation ranging from 4.2 for Ing/ml and 7.8% 
for 2 pg/ml.
For the inter-assay variation, several clinical samples were pooled and assayed 
at 2-3 dilutions in duplicate. This determination was repeated for nine (n=9) 
batches of assays over a period of three weeks. The results are illustrated in Table 
7.
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Table 7. Assay variation
a)- Intra-assay variation
4-OHA added 
1 ng/ml 
500 ng/ml 
2000 ng/ml
recovery e v %
10 96% 4.2
10 94% 4.9
10 95% 7.8
b)- Inter-assay variation
X = 37.6 ng/ml 
n =9
SD = ± 2.32 ng/ml 
C.V = 6%
X = mean value, 
n = number of assays
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Summary
Four out of five sheep responded after immunisation with 4-OHA conjugates. 
The response was markedly increased after the first boost was given although the 
magnitude of response in the case of sheep injected with 
4-OHT-17p-HS-ovalbumin was much higher than sheep injected with the conjugate 
4-OHA-7a-CET-ovalbumin.
The antiserum HP/S/1513 lA was chosen for further assay development and 
used at titre of 18K. It had an avidity of 1X1 L/M and better specificity than 
other antisera. There was no effect of volumes of 5,10 and 25 pi of neat plasma on 
the shape or the 100% binding of the standard curve
Evaluation of a chemiluminescence assay was unsuccessfully attempted while 
waiting for suitable antisera production.
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CHAPTER. FEVE
Validation of the direct RIA for 
plasma samples
Analytical Recovery
The recovery studies were carried out by the measurement of normal drug free 
plasma samples to which different known amounts of authentic 4-OHA was added. 
The recovery of the 4-OHA was also carried out from a pooled clinical sample 
which was analyzed before and after the addition of the authentic drug . The 
following concentrations were prepared : a) 1 ng/ml, was prepared by adding 10 pi 
of the standard solution 100 ng/ml to 990 pi of normal (drug-free) plasma, b) 
5ng/ml, was prepared by adding 5 pi of the standard solution 1 pg/ml to 995 pi of 
normal plasma, c) 0.5 pg/ml, was prepared by adding 5 pi of the standard solution 
0.1 mg/ml to 995 pi of normal plasma, d) 2 pg/ml, was prepared by adding 20 pi 
of the standard solution 0.1 mg/ml to 980 pi of normal plasma, e) A pooled 
clinical sample, which was measured previously and found to be 8 ng/ml (SD= ± 
1.1 ng/ml, n=5) was used to determine the recovery after spiking with 7 ng 
4-OHA. This sample was prepared by adding 7 pi of the standard solution 1 pg/ml 
to 993 pi of the pooled clinical sample. The spiked samples were left to equilibrate 
with the drug for at least 2 hours at 4 °C before the measurement. The amount of
4-OHA was measured by the direct assay for each sample in replicate and at 
different dilutions.
The results obtained (Table 8) indicated good accuracy of the procedure.
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Table 8. Analytical recovery of 4-OHA
4-OHA added 4-OHA measured recove
Drug-free plasma N.D
1 ng/ml 0.95 ± 0.04 ng/ml 95
5 ng/ml 4.85 ± 0.35 ng/ml 97
0.5 pg/ml 0.47 ± 0.023 pg/ml 94
2 pg/ml 1.9 ±0.148 pg/ml 95
patient sample 13.6 ± 1 . 6  ng/ml 90
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Parallelism
Interference from known compounds in an immunoassay can be assessed by 
cross-reactivity studies, but effects induced by unknown compounds must also be 
considered. It is possible that these effects could be due to the presence of 
cross-reacting steroids or metabolites that have not been evaluated during specificity 
studies. However, it is more likely that interference of unknown origin is due to 
substances other than steroids which affect the antibody-antigen binding reaction. 
Parallelism is the tool which can be used to investigate such interference. 
Parallelism implies that over the working range of the standard curve there is a 
linear relationship between the sample volume and the assay response. Therefore, 
if twice the sample volume is analysed, twice the mass of steroid will be detected so 
that the concentration of steroid estimated remains unchanged. Failure to achieve 
parallelism indicates that the assay is not valid and implies that the analyte in the 
sample and the standard are not reacting with the antibody in a similar fashion; one 
of the reasons for this may be that an interfering substances e.g metabolites are 
present in the sample. Parallelism studies were performed by preparing at least four 
dilutions of each of the following samples: patient pooled samples (35ng/ml, SD= 
±5ng/ml); this sample was double diluted from 1:25 to 1:200, and two quality 
control samples with high levels prepared previously at concentration of 0.5 pg/ml 
and 2 pg/ml. Sample 0.5 pg/ml was double diluted from 1:250 to 1:4000 and 
sample 2 pg/ml was double diluted from 1:1000 to 1:8000. These samples were 
treated as unknowns in the assay. The method used for plotting parallelism was the 
following: the expected value (x axis) was plotted against the observed value on y 
axis. The observed values were read from the standard curve, and the expected 
values were calculated as follows: plasma sample value divided by the dilution 
factor. The expected value for the highest concentration were taken to be the same 
as the observed values from the graph. Theoretically, the curve obtained should be 
a straight line running through the origin, with a slope of 1.0. The results are
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outlined in table 9 and indicate a slope of 1.0.
The results obtained show good parallelism indicating that the antiserum has 
good specificity and is not susceptible to interference from other compounds 
present in the samples. These results are plotted and shown in Fig.45.
Table9. Parallelism obtained with patient and quality control samples
4-OHA concentration (pg/ml)
Sample conc. Dilution factor Values observed Values expected
(X) (mean) (mean)
25 1349 1349
50 678 674
35 ng/ml 100 343 337
200 154 168
250 2873 2873
500 1384 1436
0.5 pg/ml 1000 717 718
2000 352 359
4000 169 179
1000 2115 2115
2 pg/ml 2000 1018 1057
4000 523 528
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Measurement of plasma samples with and without extraction
The extraction of steroids from serum using organic solvents is often 
considered an essential prerequisite of steroid immunoassays. This extraction is 
required either to strip the analyte from an endogenous binding protein or to achieve 
the required concentration of the steroid in the extract. In all cases, the extraction 
step introduces complexity, variability, delay and some element of hazard into the 
method, and has probably been the main factor in the inherent imprecision of some 
steroid immunoassays.
Early attempts at direct steroid assays were frustrated on three counts. Firstly, 
often the direct assay did not have adequate sensitivity ; large sample volumes were 
required, and non-steroidal components of the sample interfered with the 
antibody-antigen reaction and caused problems with liquid scintillation counting 
procedures. Secondly, the endogenous binding proteins competed with the 
antibody for the antigen and so invalidated the whole principle of the saturation 
analysis. Thirdly, the sample contained water-soluble steroids, often conjugated 
metabolites of the steroid antigen, which cross-reacted with the antibody in the 
direct assay. However, in the past, antisera were produced to certain steroid 
compounds that are of high avidity and excellent specificity (Bermudez et al.. 1975; 
Uscheva et al.. 1986). The improved quality of antiserum results in an increase in 
sensitivity, which means that sample volumes may be reduced. Improved 
specificity has reduced, to manageable proportions, the cross-reactivity from related 
metabolites.
To date, most success in the development of direct steroid assays has been 
achieved with C21 steroids which normally bind to Cortisol-Binding Globulin 
(CBG). Several direct assays have now been published for cortisol (Hunter and 
Corrie, 1983), progesterone (Ratcliffe et al., 1982), oestradiol (Mertens et al..
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1983) and aldosterone (Jaffe and Behrman, 1979). Less success has been 
achieved for the Cjp steroids that bind to Sex Hormone-Binding Globulin
(SHBG). 4-OHA is a Cjp steroid which is similar in structure to AD and T . 
Therefore, in order to develop a direct immunoassay for 4-OHA, the antiserum 
raised must possess high avidity and specificity. However, if this antiserum did 
not have these qualities then there is no alternative but to adopt some elaborate 
sample processing steps as integral parts of the assay. These procedures may not 
only involve a solvent extraction, but also chromatographic purification from AD 
and other metabolites which otherwise could make the assay unsatisfactory. So, 
validation of the method before and after the solvent extraction is a vital step in 
order to claim that the assay is "direct".
The extraction of plasma samples has often been carried out using the 
solvent mixture diethylether: dichlormethane (4:l,vA^) although other solvents such 
as ether, ethyl acetate and dichlormethane, gave more than 85% recovery when 
3H-4-OHA was extracted from plasma samples. The selection of this solvent 
combination had more to do with convenience of easy evaporation to dryness than 
to any other consideration. The extraction procedures are described in Chapter 2 . 
Each sample was assayed before and after extraction at three different dilutions. 
The recovery of the spiked sample after extraction was 80% which compares 
favourably with the results obtained from the clinical samples after extraction 
indicating that the loss in the recovery is due to the extraction procedure itself. The 
results obtained are presented in a histogram (Fig.46).
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Application of clinical samples on Lipidex 5000 and 
the detection of the immunoreactive fractions
The properties of Lipidex 5000 have been described in the Materials and 
Method Chapter. The Lipidex columns were used here to separate the steroid 
components of the plasma samples into small fractions and then measuring these 
fractions for the detection of any immunoreactivity present against the antisera 
HP/S/1513 lA and HP/S/A2 lA. This is necessary in order to investigate the 
possibility of other components i.e unknown metabolites, crossreacting with the 
antisera therefore giving false positive values for 4-OHA. The t.l.c. technique was 
used for this purpose before trying Lipidex but failed because of the poor 
consistency, reproducibility and the difficulties encountered particularly when 
extracting small silica sections of the tl.c.
Three patient samples, were extracted twice with five volumes of solvent 
(ethendichlormethane, 4:1). The residues were redissolved in 2x75 pi 
trimethylpentane: isopropanol (1:5) and were applied to 18 cm columns of Lipidex 
5000 in 2 ml disposable glass pipettes. Twenty fractions (0.25 ml) were collected 
and assayed by the 'direct' RIA after evaporation and redissolving in assay buffer. 
The elution profile of 4-OHA, AD, T and 4-OHT were studied by applying tritiated 
4-OHA, AD, T and unlabelled 4-OHT to Lipidex columns and collecting column 
fractions in the same way as the samples. These fractions were monitored for 
radioactivity and in the case of 4-OHT for immunoreactivity. Authentic cold 
4-OHA was also applied to Lipidex to investigate if there was any difference 
between the chromatography of the radioactive and unlabelled 4-OHA on Lipidex 
50(X) column. The elution patterns of these steroids are shown in Fig. 47 . All 
patient samples showed an identical immunoreactivity profile as the radioactive and 
unlabelled 4-OHA indicating that the measured component in these samples is very
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likely to be 4-OHA. Fig. 48 illustrates the immunoreactivity profiles of a patient 
sample against the antiserum HP/S/1513 lA together with such profiles of plasma 
to which 4-OHA was added. It also shows the corresponding elution of 
radioactivity where a plasma sample, enriched with 3H-4-OHA, was separated on 
Lipidex.
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^H-T after chromatography on Lipidex columns.
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Plasma 4-OHA RIA: Direct assay vs assay after 
chromatographic purification
The use of Lipidex in the separation of 4-OHA from AD has been described by 
Dowsett etal (1987). In this method, plasma levels (>300pg/ml) of 4-OHA were 
measured using a radioimmunoassay for AD and utilizing antibodies with a 25% 
cross-reactivity with 4-OHA. The method required solvent extraction and 
application of the extract residue on Lipidex 5CXX) for purification. The overall 
recovery quoted in the method varied between 25 and 50%. The sensitivity of the 
assay was 0.3 ng/ml, and the within- and between assay coefficient of variations 
were 14.1% (n=16) and 18% (n=7) respectively at a 4-OHA concentration of 10 
ng/ml which is a point in the middle of the standard curve
Although the above method is tedious and the recovery was poor, it can be of 
use for evaluating any new method for 4-OHA. Plasma samples, obtained during a 
clinical trial or with added 4-OHA were assayed directly and after chromatography 
on Lipidex 50(X). Prior to application on the column, plasma extracts were taken 
for monitoring the recovery of 4-OHA at this stage of the procedure. The fractions 
from the column were collected, evaporated to dryness and redissolved in 0.5 ml of 
assay buffer. The redissolved fractions were allowed to stand at 37 °C in a water 
bath to ensure that the 4-OHA remained in solution at the time of the assay. In 
parallel experiments, an aliquot (10 pi, approx. 250,000cpm) of ^H-4-OHA was 
added to 1 ml of normal plasma and left for 30 minutes on the bench to equilibrate 
before extraction and column chromatography. A portion (0.25ml) of this plasma 
was extracted and the recovery of radioactivity was found to be 92% . The 
radioactive residue was then dissolved in 2x75 pi aliquots of the eluting solvent 
(trimethylpentane: isopropanol, 1:5) and applied to the column. The column 
fractions were collected and the radioactivity counted in each fraction (Table 10). 
Most of the radioactivity was found in the fractions in the region between 3.25 to
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3.75 ml (fractions 10 and 11) of the eluant amounting to 94% of the radioactivity 
applied to the column. This means an overall recovery of 87% was achieved for the 
original plasma sample. For other spiked and clinical samples which were 
processed in the same way, immunoreactivity was only detected in fractions 
corresponding to the previously established position of 4-OHA (i.e: between 3.25 
to 3.75 ml of column eluant).
Table 11 shows the immunoreactive profile of one of the clinical samples 
(pooled plasma sample) from a patient treated with 250mg 4-OHA orally. Direct 
RIA of the sample gave a 4-OHA value of 52.2 ng/ml. An aliquot of this plasma 
(0.15ml) was extracted with 2 x 2 ml of the solvent mixture, ethendichlormethane 
(4:1, v/v). The organic solvent extracts were combined (4ml) and a portion (0.5 
ml) was transferred to another tube to determine the recovery of 4-OHA at this 
stage. The amount of 4-OHA found in this 0.5ml extract was 965pg indicating a 
recovery of 98% . The remaining extract (3.5ml), which should contain 6755 pg of 
4-OHA , was dried and the residue was then redissolved in 2 x 75 pi 
trimethylpentane:isopropanol (1:5, v/v) and applied to a Lipidex column. Fractions 
were collected from the columns on elution with trimethylpentane:isopropanol (1:5, 
v/v). After evaporation, these fractions were redissolved in assay buffer and 
quantified by the 4-OHA RIA. Table 11 shows the amounts of 4-OHA detected in 
every fraction eluted from the column; it also shows that the total amount detected in 
all fractions was 4450pg. This means that the recovery from the column was 66% . 
Since the recovery during the extraction stage was 98%, the overall recovery 
calculated for the whole procedure was 65% . The diagram below simplifies the 
above calculations. Results obtained with the three samples including sample 3 are 
given in the appendix. Also given are the recovery data obtained in the three stages 
namely the extraction, the Lipidex column chromatography and the overall 
recovery.
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Table 10. The radioactivity profQe of the ^H-4-OHA spiked plasma
Fraction No. fraction vol. Radioactivity Recovery
(ml) (cpm) (%)
1 1 6.7 _
2 0.5 6
3 0.5 5
4 0.2 17.7
5 0.2 30.3
6 0.2 93
7 0.2 862 1.4
8 0.2 2306 3.8
9 0.2 3525 5.8
10 0.2 27653 46
11 0.2 23287 38.7
12 0.2 1780 3
13 0.2 399 0.6
Total = 97.2%
137 C hapter 5
Table 11. Examination of a plasma sample collected after extraction and
chromatography purification
Patient sample 
4-OHA, direct RIA 52.2ng/ml)
1
0.15 ml extracted with 4 ml 
organic solvent 
0.5ml assayed for 4-OHA
I
Extract 4-OHA
expected =7830pg 
found =7728pg 
recovery =98%
Column chromatography
1
Fractions collected and 
assayed for 4-OHA
4-OHA
expected =7728pg 
found =5085pg 
recovery =66%
Recovery from the whole 
procedure = 65%
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Table 12 The immunoreactivity profile of a plasma sample
Fraction ml eluted fraction vol.(ml) 4-OHA detected(pg)
1
2
3
4
5
6
7
8
9
10 
11 
12
13
14
1
1.5
1.75 
2
2.25
2.5
2.75
3
3.25
3.5
3.75
4
4.5
5
1
0.5
0.25
0.25
0.25
0.25
0.25
0.25
0.25
0.25
0.25
0.25
0.5
0.5
N.D
N.D
N.D
N.D
N.D
N.D
N.D
210
1032
1902
1140
166
N.D
N.D
Total 4-OHA eluted 4450
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Determination of 4-OHA binding to plasma protein:
Steroids in plasma are bound to a large extent to proteins. Although albumin is 
the major protein to bind steroids quantitatively, from the analytical point of view 
specific proteins such as CBG and SHBG are likely to be more important than 
albumin. This is because such proteins bind much more strongly to steroids than 
albumin and this results in interference with the immunoassay especially if the 
antiserum has a similar or lower binding affinity (Ka) to that of specific proteins . 
The binding affinities of plasma proteins to steroids differ widely. For example, T 
binds to albumin with the binding affinity of 3.7 X 10  ^L/M and to CËG with Ka 
of 1.4 X 10  ^L/M and to SHBG with Ka of 2 X 10  ^L/M. Fortunately, only a 
small portion of this androgen is bound to protein but even this small portion could 
disturb the equilibrium between the androgen and its specific antibody if the 
antibody does not possess a much higher Ka.
4-OHA is similar in structure to T and AD, therefore it may have similar protein 
binding properties in the plasma and interference from these proteins should be 
considered when an immunoassay for its measurement in plasma is being 
developed.
The extent to which 4-OHA was bound to protein in the plasma was determined 
by the Equilibrium Dialysis method using small dialysis cells (Horowitz and 
Barnes, 1983). Each cell was composed of two compartments separated by a 
dialysis membrane. The plasma samples (Iml)were placed in one compartment, and 
the second compartment, contained the same volume of assay buffer. Five cells 
were used in a set for this purpose: cell 1 and 2 contained the same pooled clinical 
sample. The first cell was put at 4 °C, and the second cell was allowed to stand at 
room temperature. Cell 3 contained a clinical sample spiked with tritiated 4-OHA 
and cells 4 and 5 contained spiked plasma samples containing high and low
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concentration of 4-OHA. Samples
were assayed before and after dialysis using the direct RIA. At the same time, a 
sample from the buffer compartment of each cell was assayed to determine the 
amount of free drug that dialysed through the membrane into the buffer. The free 
drug found in the buffer compartment was multiplied by two because the free drug 
is expected to be distributed equally between the two compartments (i.e it is at 
equilibrium). Table 13 gives the results of this experiment. Up to 15% of 4-OHA 
was found in the free form and when cells were maintained at 4 °C, the free form 
was only 7% of the total.
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Comparison of 4-OHA RIA with a published method
For the purpose of validating the described RIA, it was applied to plasma 
samples which had been previously analysed elsewhere for 4-OHA. Three batches 
of plasma samples were collected from subjects who received 4-OHA at the Chelsea 
Hospital for Women (CHW) and analysed there by the method based on the AD 
antibody RIA (Dowsett et al. 19871. This latter method will be referred to as 
"indirect" as opposed to the present "direct" RIA. The period of storage of these 
samples varied from batch to batch and this was not very helpful for this study as 
the "indirect" method was continuously under minor modifications.
Batch 1: This was the first batch of samples and consisted of 26 samples from 
two male volunteers , each of whom was given a single injection (500mg, i.m) of 
4-OHA. The results obtained by the direct RIA together with the results obtained 
by the 'indirect' method are given in Table 14.
Statistical analysis: The plasma 4-OHA levels obtained by the two method are 
given in Fig. 49. Whereas the drug level obtained by both methods has the same 
general pattern, the values obtained by the direct RIA were consistently higher.
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Table 14. Results comparison between the "Direct" and "Indirect" RIA.
Sample no Time (hrs) 4-OHA Cone. (X, ng/ml)
Patient 1 Direct Indirect
1
2
3
4
5
6
7
8
9
10  
11 
12 
13
0
0.17
0.33
0.67
1 . 0
1.5
2
3
4 
6 
8 
12 
24
< 0 . 0 2
0.3
11.3
19
20 
14 
35 
25
16.4 
13.7 
11 
19
8
< 0 . 8
< 0 . 8
5
5.9
11.4
7.2
12.5
12. 2
9.7 
3.5
1.8 
1.2
< 0 . 8
Patient 2
< 0 . 8
< 0 . 2
14
15 0.17
0.33
0.67 12
30.3
24.2
24.5
19.8
19.9
20
67
56
64
49
29
13
12
18
20
22
23
24
25
26
12
24 < 0 . 8
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Fig. 49: Correlation between plasma 4-OHA values obtained by 'direct' and
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Batch 2: This batch of samples consisted of 40 clinical samples taken 6om 5 male 
volunteers as follows: samples 1-9 (subject 1), 10-18 (subject 2), 19-27 (subject 
3), 28-36 (subject 4). The first five samples from subjects 1-4 were collected after 
250 mg oral dose of 4-OHA at the following time points after administration: 
5min, 1 ,3 ,6 , and 12 hours. The next four samples were taken after injecting 250 
mg of 4-OHA (i.m) two weeks after the oral administration. These samples were 
taken at the following time points: 1, 4, 7 and 14 days after injection. The same 
protocol was also used for subject 5 except that he was not given an oral dose 
earlier (Table 15). The results obtained by the direct RIA and the indirect method 
are presented in Table 16. For the samples collected after the oral dose, the direct 
RIA gave higher values, almost double, those reported by the indirect method. It 
was the reverse, on the other hand, with the specimens taken after the i.m dose. 
However, the two methods correlated well particularly for the samples following 
the i.m dose. Fig. 50 shows the correalation obtained between the direct and 
indirect methods.
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Table 16. Comparison of plasma 4-OHA values obtained by two methods
Sample
Time
Mean 4-OHA Cone, (ng/ml)
Subject 1 Direct RIA Indirect RIA
1 5min 5.5 10
2 1h 63.9 35
3 3h 69 42
4 6h 18.9 9.3
5 12h 6 3.1
6 Iday 4.1 11
7 4day 3 6.3
8 7day 5.2 12
9 14day 2.1 4.4
Subject 2
10 5min 20 19
11 1h 70 42
12 3h 29 26
13 6h 22 11
14 12h 7.2 5.2
15 Iday 11.2 27
16 4day 2.8 3.3
17 7day 0.75 2.3
18 14day N.D 2.2
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Subject 3
19 5min 4.9 1 .2
20 1h 46 26
21 3h 38 16
22 6h 9.7 12
23 12h 4.2 9.4
24 Iday 4.7 15
25 4day 3.3 14
26 7day 1.8 3.3
27 14day N.D 1.9
Subject 4
28 5min 3.6 15
29 1h 46 37
30 3h 29 31
31 6h 8 18
32 12h 2.8 <0.8
33 Iday 3.5 11
34 4day 2.2 9.4
35 7day 2 7.5
36 14day 0.63 3.9
Subject 5
37 Iday 13.9 29
38 4day 4.8 6.6
39 7day 2.3 3.5
40 14day 3.4 7.1
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Statistical data
Table 17 shows a summary of the statistical equations for each patient samples, 
for all oral samples and i.m samples collectively, and for the complete batch of 40 
samples.
Table 17. Statistical analysis of data from samples (Batch 2)
Sample
Regression line 
(through zero)
Regression line 
(1 inear) (r)
Patient 1: oral 
i .m
y -0 .5 4 3 3  * X 
Y-2.2965 * X
Y -0 .54  * X + 2 .1 3  
Y -2 .64  * X - 1 .0 8
0.98
0.97
Patient 2: oral 
i .m
Y-0.7338 * X 
Y-4.41 * X
Y-0.56 * X + 3.84 
Y-2.35 * X - 0.1
0.95
0.98
Patient 3: oral 
i .m
Y-0.9413 * X 
Y-4.69 * X
Y-0.40 ♦ X + 4.63 
Y-3.33 * X + 0.21
0.88
0.94
Patient 4: oral 
i .m
Y-1.751 * X 
Y*4.34 * X
Y-0.67 * X + 8.20 
Y-2.51 * X + 2.7
0.91
0.97
Patient 5: i.m Y-1.7678 * X Y-2.19 * X - 1.85 0.99
All oral samples Y-1.0467 * X Y-0.52 * X + 5.32 0.9
All i.m samples Y*3.5 * X Y-2.1 * X + 1.5 0.94
All samples Y-2.2743 * X Y-0.52 * X + 6.28 0.86
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Batch 3: this batch, comprising of 24 samples, was collected and analysed 
recently at CHW by the indirect RIA. Details of the samples were not fully 
available. However, these samples were taken from 4 patients each of whom was 
given 500 mg of 4-OHA by intramuscular injection. The results of this study are 
given in table 18 and the regression line obtained is shown in figure 51. The figure 
shows the plasma 4-OHA patterns obtained by the two methods. Because of the 
profound discrepancy between the results obtained by the two methods, with regard 
to samples 12 and 21, these values were excluded from the calculation of the 
regression line.
Table 18. Comparison of data (Batch 3)
Sample
Mean 4-OHA Cone, (ng/ml)
Direct RIA Indirect RIA
1 5.3 2.7
2 12.2 5.9
3 6.9 3.3
4 3.8 1.7
5 4.4 1 .8
6 2.4 1.1
7 0.14 <0.5
8 0.22 <0.5
9 4 3.1
10 5.6 3.7
11 7.2 4.2
12 30 1 .8
13 2.2 1.1
14 1 .5 1.6
15 14.5 7.1
16 5.8 2.9
17 4.4 1 .5
18 1.6 <0.5
19 0.15 <0.5
20 3.2 3.1
21 3.2 17
22 3.2 4
23 3 2.2
24 1 .2 1
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Simultaneous analyses of plasma samples by two methods
Samples were analysed in parallel, by the direct and indirect RIAs. The subject 
received 4-OHA 500 mg, im. In the indirect assay, plasma samples (4) were 
extracted, chromatographed and measured with the RIA using the AD antiserum. 
The same samples were transferred to Guildford and the neat plasma was used for 
the direct RIA. The results obtained are presented in Fig. 52. These results show 
better agreement than those obtained previously when the correlation studies were 
not earned out at the same time.
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4-OHA RIA : Possible interference from a suspected 
metabolite 4-OHT
The purpose of this experiment was to investigate whether 4-OHT, a putative 
metabolite of 4-OHA, does exist in patient samples and if it does, to what extent. 
The clinical sample was taken from a patient given an oral dose of 4-OHA. The 
problem was addressed by extracting and applying the clinical sample onto a 
Lipidex 5000 column. Then three different antibodies with different crossreactivity 
towards 4-OHT were used to monitor the immunoreactivity in the fractions eluted 
from the column. The antibodies used were : HP/S/1513 lA which cross-reacts by 
60% with 4-OHT, HP/S/A2 1A which does not cross-react with 4-OHT (less than 
0.1%), both are specific antisera to 4-OHA and the third antibody used was raised 
against AD (Guildhay Antisera Ltd) and does not crossreact at all with 4-OHT but 
does crossreact by 25% with 4-OHA (the same antibody used in the indirect RIA).
The details of the samples used for the above puipose are given below:
1- 4-OHA spiked plasma (lOng/ml)
2- 4-OHT spiked plasma (lOng/ml)
3- A mixture of 4-OHA and 4-OHT spiked plasma (lOng/ml each)
4- plasma sample taken after 60 minutes after oral ingestion (250mg)
5- 3H-4-OHA spiked plasma
6- ^H-AD spiked plasma
7- % -T spiked plasma
Columns: Glass pipettes columns (2ml, Volac) were pre-washed with the eluting 
system trimethylpentane:isopropanol (5:1, v/v); then each column was packed with
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Lipidex to the same height Samples were extracted, and the extracts applied in 75 
pi of the eluting system using long glass pasteur pipettes. Fractions were collected 
from the column in the following way:
Sample Collection
4-OHA 6 X 0.5ml fractions plus 8 X 0.2ml
4-OHT 5 X 0.5ml fractions plus 10 X 0.2ml
Mixture sample 5 X 0.5ml fractions plus 10 X 0.2ml
Patient 3 X 0.5ml fractions plus 15 X 0.2ml
Radioactive samples 16 X 0.25ml fractions plus 1 X 0.5ml
Fractions were evaporated to dryness at 37 °C and the residue redissolved in 
assay buffer (1ml). Radioactive fractions were collected directly into scintillation 
vials and counted after mixing with scintillation fluid (Optiphase). The results 
obtained from these radioactive samples are shown in Table 19. These results 
show that : 3H-4-OHA was eluted between 3.25 to 4 ml, ^H-AD was eluted 
between 2.50 to 3 ml and ^H-T was eluted between 2.25 to 2.75 ml. The elution 
patterns was in agreement throughout the validation experiments.
Table 20 shows the immunoreactivity detected in the fractions of the unlabelled 
spiked and the clinical samples using the antiserum HP/S/1513 lA. The Table also 
shows the immunoreactivity profile obtained when patient fractions were analysed 
by using the AD antiserum HP/S/665 1A which does not crossreact with 4-OHT ( 
<0.1% ). Figs. 53 and 54 show these results using both antisera (HP/S/1513 lA 
and HP/S/A2 lA). In Fig. 53 most of the immunoreactivity detected in the 
fractions of the clinical sample ( >66% ) was found between 3.3ml and 3.7ml ( 
Table 20).
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Table 19: The radioactivity detected (dpm) in fractions eluted from the Lipidex 
columns.
Fraction eluted(ml) 4-OHA % AD % T %
1 0.25 92 - 50 - 75 -
2 0.50 85 - 67 - 75 -
3 0.75 60 - 90 - 102 -
4 1.00 95 - 132 - 85 -
5 1.25 105 - 90 - 107 -
6 1 .50 100 - 100 - 137 -
7 1.75 140 - 197 - 175 -
8 2.00 345 0.1 450 - 1015 0.6
9 2.25 1015 0.3 2832 1.8 27375 16.4
10 2.50 4815 1.6 47841 30.4 10396 62.3
11 2.75 10255 3.3 87762 55.8 30177 18.1
12 3.00 9030 3.1 1381 8.7 2062 1.2
13 3.25 12527 4.1 2137 1 .3 557 0.3
14 3.50 52227 17.1 787 - 282 -
15 3.75 119477 39.2 380 - 240 -
16 4.00 76977 25.2 212 - 247 -
17 4.50 18100 5.9 277 - 550 -
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Table 20: Immunoreactivity in column fractions.
Sample Eluted (ml)
Immunoreactivity(% of total)
HP/S/1513 1A HP/S/665 1A
3.0-3.3 6.5
4-OHA 3.3-3.6 43
added 3.6-3.8 33.4
3.8-4.0 14
4.0-4.2 2.4
2.7-2.9 8.8
4-OHT 2.9-3.1 38.4
added 3.1-3.3 37.7
3.3-3 .5 13.2
3.5-3.7 1.7
2.7-2.9 6.6
Mixture of 2.9-3.1 10.8
4-OHA and 3.1-3.3 10.6
4-OHT 3.3-3.5 25.4
3.5-3.7 27.7
3.7-3.9 16.2
3.9-4.1 2.5
2.3-2.5 2.2
2.5-2.7 6.3
2.7-2.9 1 8.5
Clinical 2.9-3.1 2 5.6
3.1-3.3 15.4 13
3.3-3.5 22.8 23
3.5-3.7 43.8 27
3.7-3.9 13.5 12.4
3.9-4.1 1.3 1.8
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Summary
A direct RIA for the measurement of 4-OHA in plasma has been validated. The 
results of the analysis of female plasma enriched with 4-OHA at several 
concentrations and dilutions showed above 90% recovery.
Parallelism studies conducted with a plasma sample from a subject received a 
dose of 4-OHA and samples to which the drug had been added gave a satisfactory 
correlation between the expected values and those obtained by the direct RIA.
Plasma samples with added 4-OHA and test samples were analysed by direct 
RIA and after extraction. The extract gave over 80% of the value from direct assay. 
When test plasma extract was run on a Lipidex column, the elution pattern of 
immunoreactivity superimposed on immunoreactivity or radioactivity obtained with 
corresponding fractions from plasma to which 4-OHA or 3H-4-OHA was added.
Plasma protein binding of 4-OHA was carried out using the equilibrium dialysis 
method. 4-OHA was protein-bound up to 85% at 20 °C.
Using HP/S/A2 antiserum (with no cross-reactivity with 4-OHT) in the RIA to 
analyse the column fractions from 4-OHT-enriched and authentic plasma, no 
significant immunoreactivity was observed.
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Pharmacokinetics of 4-OHA in the 
rat and rabbit
Introduction
As a possible drug candidate 4-OHA is somewhat unusual in that it has not been 
subject to the routine detailed investigation protocol in animals prior to clinical trials 
in man. Thus little is known about the persistance of 4-OHA in blood and the way 
drug concentration in body fluids is influenced by the route of 4-OHA 
administration.
Once a validated RIA method was developed for 4-OHA, studies were 
undertaken to investigate the plasma pharmacokinetics of 4-OHA in two animal 
species, rat and rabbit.
Dosing with 4-OHA
The solubility characteristics of 4-OHA made the selection of an efficient vehicle 
difficult. For the first rabbit experiment and the chronopharmacokinetic 
experiments the dosing solution contained ethanol (900 pi), 1,2 propandiol (1.1ml) 
and Tween 80 (20 pi). This vehicle failed to ensure a proper homogeneous 
suspension and the drug precipitated quickly without constant stirring. However, 
measurement of the remaining drug after injection gave a good indication of the 
amount injected into the animal. After further search, another dosing vehicle was 
used for the subsequent rabbit experiment. The composition of this mixture ( Wu 
and Lini; 1982) ) was Nad (90mg), sodium carboxymethyl celloluse (50mg), 
Tween 80 (40 pi) and benzyl alcohol (90 pi). These ingredients were dissolved in 
10 ml of distilled water and mixed constantly prior to injection. This medium gave 
a better homogeneity than the vehicle used before.
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1- The pharmacokinetics of 4-OHA in the rabbit
Pharmacokinetic studies were carried out in two New Zealand white rabbits 
(3kg and 5.5kg). A single i.m (25mg/kg) injection of 4-OHA was given in the hind 
leg. The dosing solution in this experiment was composed of ethanol (900 pi), 1,2 
propandiol (1.1ml) and Tween 80 (20 pi). Blood samples were collected from the 
marginal ear veins. For the first experiment: samples were collected into 
heparinised tubes at the following time points after dose: O min, 5 min, 10 min, 20 
min, 30 min, 45 min, 60 min, 85 min, 2 h, 3 h, 4 h, 5 h, 6 h, 6 h, 24 h, 48 h, 72 
h, day 6, day 7 and day 8. The samples were stored at -20 until assay. For the 
second experiment, which used a different vehicle (Wu and Lini, 1982). Samples 
were collected into Eppendorf plastic vials at 0 min, 5 min, 15 min, 30 min, 45 
min, 60 min, 90 min, 2 h, 3 h, 4 h, 5 h, 6 h, 22 h, 29 h, 48 h, 72 h and 96 h after 
dose. The serum was stored at -20 until assay.
Results 
Experiment 1
The results of this experiment are shown in Table 21 and Fig. 55. The plasma 
levels of 4-OHA in the rabbit obtained in this experiment indicated that for the first 
3 hours the 4-OHA levels attained were around Ing/ml and thereafter rose to over 
6ng/ml at 5h. Six hours after injection, the level fell to 1.4 ng/ml and subsequently 
remained steady for a period of over 1 week. It could be argued that the late peak is 
the result of the biliary excretion of the glucuronide form of the drug and 
reabsorption after hydrolysis. However, the low levels measured of the drug 
confirm the suggestion that 4-OHA is rapidly and extensively conjugated (Dowsett 
et al.. 1987).
165 C hapter 6
Experiment 2
In contrast to the first experiment, in the second rabbit which was injected with 
drug in a different vehicle, 4-OHA maintained steady plasma levels, after a similar 
dose, throughout a period of 96 hours post i.m administration. The drug level 
ranged between 7.5 and 18.5 ng/ml (Table 22 and Fig. 56 and Fig. 57). The 
steadiness of drug concentration may be explained either by the slow absorption of 
4-OHA from the site of injection (depot effect) or by the redistribution of the drug 
between different compartments. This may be responsible for the reported long 
lasting effects of this drug which is reflected in the long lasting suppression of the 
oestrogen level in animals and human (Dowsett et al.. 1987; Brodie et al.. 1986). 
The difference observed in 4-OHA plasma levels in these two experiments may be 
caused by the higher efficiency of the second dosing vehicle.
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Table21. The plasma levels of 4-OHA after a single i.m injection (25 mg/kg) into 
rabbit.
Time 4-OHA concentration (ng/ml)
0
5min
lOmin
20min
30min
45min
60min
85min
2h
3h
4h
5h
6h
24h
48h
72h
Day6
Day7
Day8
Day9
N.D
0.36
0.32
0.35
1.24
0.64
0.73
0.80
0.67
0.86
2.3
6.3
1.4
2.5 
1
1.23
1.6 
1
0.66
0.6
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Table 22. Plasma levels of 4-OHA in a rabbit aftera single i.m injection of 4-OHA 
(25 mg/kg).
Time 4-OHA concentration (ng/ml)
5min
30min
45min
60min
90min
2h
3h
4h
5h
6h
22h
29h
48h
72h
96h
15.9
13.5
13.7
10.8
18.5
16.7 
12.2
13.1
9.9
10.6
11.8
11.2 
8.2 
10.2 
7.5
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Fig. 55: Plasma concentration of 4-OHA after i.m injection to a rabbit (Expt.l, 25
mg/kg)
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Fig. 56: Plasma concentration of 4-OHA after a single i.m injection to a rabbit
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2- Pharmacokinetics of 4-OHA in the rat 
after oral administration
Introduction
Pharmacokinetic studies using [6,7 3HJ4-OHA have shown that there is a 
marked difference in urinary and faecal excretion of 4-OHA between male and 
female rats (personal communication, Ciba Geigy, Horsham). There has been little 
work reported on the dose and pharmacokinetic proportionality. Therefore, this 
study was designed to assess the pharmacokinetic differences between male and 
female rats using the direct RIA. The study was also designed to investigate plasma
4-OHA levels in male rats at various doses of the drug.
Materials and Methods
The study was carried out using Wistar Albino male and female rats. The 
average weight of rats used was about 250 grams (230-265g). The drug (4-OHA) 
was administered to the rats through the mouth by oral lavage using a syringe. The 
dosing vehicle was prepared by dissolving the drug in polyethylene glycol 400 
(PEG 400) and diluting with de-ionised water (78% PEG and 22% water). The 
volume given to the rats varied from 0.5 to 1.5 ml depending on the dose level 
used.
These studies were preceeded by a separate pilot study carried out on one male 
rat to assess the feasibility of using 8 mg/kg 4-OHA p.o., to produce measurable 
plasma levels of 4-OHA using the direct RIA. Blood samples were collected from 
the tail vein at the following time points: 30, 60, 90, 120 minutes, 3, 4, 6, 8, 24, 
36, and 72 hours. The results obtained from the pilot study were assessed and the 
dose range of 8,16 and 32 mg/kg was selected for these experiments.
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Three groups of six male rats and one group of female rats were dosed orally. 
Each group was given a different dose: 8 mg/kg for group 1,16 mg/kg for group 2, 
32 mg/kg for group 3. All three groups were male. Group 4 was female and dosed 
with 16 mg/kg. Blood samples were collected from the tail vein at 0.5, 1, 1.5, 2, 
3, 4, 5, 6, 7, 24, 32, and 48 hours post-dosing. Blood samples were allowed to 
clot and serum collected as soon as possible and stored at -20 ®C until assayed.
R esults
The results obtained from the pilot study showed that 4 hours after 
administration the drug level in the plasma reached its peak (1.8 ng/ml). However, 
48h after administration, the 4-OHA serum levels were undetectable using the 
direct RIA.
Group 1
This group (6 male rats) was given 8 mg/kg dose and blood samples were 
collected until the following day. The results which are given in Table 23 indicate 
that variation exists between individual rats when comparing values obtained for 
each time point. However, there has been a consistent pharmacokinetic profile for 
all rats in this group when every individual rat is assessed independently. This 
consistency is best illustrated in the late peak of the drug concentration in the 
serum. Fig. 58 represents the semm concentrations profile in individual rats in this 
group and the mean value for each time point
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Fig. 58: Serum concentrations of 4-OHA in male rats after an oral dose (8 mg/kg)
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Group 2
This group ( 6 male rats) was given 16 mg/kg dose. Serum was separated from 
blood as soon as possible and assayed immediately. The results obtained from this 
group are shown in Table 24 and Fig. 59. In these results 3 out of 6 rats showed a 
huge increase of 4-OHA levels in the serum at different points after drug 
administration. This increase occurred 30 minutes after administration in rat 
number 3, whereas rat number 4 showed the surge after 6 hours and rat number 5 
after 5 hours from administration. Other rats did not show such a significant 
increase in the drug level except for rat number 6 which showed a relatively 
moderate increase 4 hours post-dosing. Also significant in this group is the 
presence of at least two peaks of the drug level. The first blood sample from each 
rat which was taken between 30 to 40 minutes after drug administration showed 
higher values than samples collected at 60 minutes after administration almost in 
every rat (except rat number 6). All rats showed a peak of different magnitude 
(5.6-14.8 ng/ml in most rats except 34 and 47 ng/ml in two rats) between 3 and 5 
hours after drug administration. This supports the previous results obtained from 
the studies of the pharmacokinetics in rabbits after administrating 4-OHA i.m . The 
possible explanation could be the drug excretion and reabsorption from bile.
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Group 3
This group ( 6 male rats ) was administered 32 mg/kg dose. Serum was 
separated as soon as possible and stored at -20 °C before assay. Table 25 shows 
the results obtained from this group and Fig. 60 represents the pharmacokinetic 
profiles of 4-OHA in the 6 rats.
The results from group 3 show similar pattern to group 2; more than one peak 
for each pharmacokinetic profile, but the magnitude of these peaks was not as high 
as in group 2 (4.23-8.56 ng/ml in 4 rats and up to 17 ng/ml in 2 rats). Most of the 
peaks observed appeared 90 minutes and 4 hours after drug administration.
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Group 4
This experiment was carried out to investigate any significant differencesin the 
pharmacokinetics of 4-OHA between male and female rats. The group of female 
rats was dosed orally with 16 mg/kg of the drug. Blood samples was allowed to 
clot and serum separated as soon as possible. The samples were stored at -20 
and assayed the following day. The results obtained from this group are outlined in 
Table 26 and the mean of the drug level in six rats for each time point is shown in 
Fig. 61. The mean of the plasma 4-OHA concentration profiles in all groups of 
rats are shown collectively in Fig. 62.
There were marked differences in the serum drug levels after oral administration 
of 4-OHA between male and female rats. Female rats showed much higher drug 
levels than male rats ( 3 times higher ). This may fit well with the recent data 
obtained by Ciba-Geigy (personal communications) when 3H-4-OHA was injected 
into male and female rats. Female rats showed higher radioactivity in the urine 
than that observed in males. This may reflect higher plasma levels and higher renal 
filtration of the drug. Furthermore, Gower (1984) concluded that in rats, there are 
sex differences in hepatic metabolism of steroids. Male rats, show a higher 
hydroxylating activity than females.
Two other important observations were noted, the first was that the consistancy 
of the faeces of the male rats was invariably "loose", whereas, the female excreta 
was normal. The second observation was that 24 hours after administration the 
drug level was only 4.3% of the previous sample (7th hour sample), whereas in the 
male rats it accounted for 30% . This may have significant pharmacological 
implications if it was tme for humans.
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Comparison of 8, 16 and 32 mg/kg in male rats
D ata analysis: The serum 4-OHA profile, area under the serum
concentration/time curve (AUC), peak serum concentration (Cmax) and time to 
peak (Tmax) were compared between groups 1,2 and 3 of male rats.
All averaged data are presented as mean ±1 standard deviation (SD) unless 
otherwise stated.
I nter-animal variation, (CV%), was assessed for each group for serum 
concentration, AUC and Cmax using the following expression:
SD
%CV=-----------xlOO
Mean
Serum 4-OHA concentrations
4-OHA was detected in the serum of all male rats by 0.5h (Tables 24-26, Figs. 
58-60). However, the median serum concentration at 0.5h of the group 2 
(32mg/kg) was approximately 7 times that of group 1 (8mg/kg), (4.45 ng/ml 
compared to 0.69 ng/ml respectively), and comparable to that of group 3 which 
received 32 mg/kg (4.45 ng/ml compared to 3.1 ng/ml). The median serum 4-OHA 
concentration profiles for all groups of rats are shown in Fig. 63.
The drug, 4-OHA, was detected at 48h in the serum of 3 rats in group 1, all 
rats of group 2 and only 3 rats in group 3. However, only 2 rats showed detectable 
levels of 4-OHA in group 3 at 72h (0.1 ng/ml).
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The irregularities in the serum 4-OHA concentration profile and the relatively 
short time of sampling, (7-48 hours), precluded calculation of the elimination rate 
constant, (Kel), of 4-OHA for the 3 groups. Drug levels fluctuated in a markedly 
irregular fashion thus resulting in, for example in the 8mg/kg dosage group mean 
4-OHA values of 0.7 to 1.9 ng/ml during the 0.5-7.0h post-dose. Corresponding 
ranges for the 16 mg/kg (male), 16 mg/kg (female) and 32 mg/kg dosage groups 
were 3.3-16,13-23.2 and 3.3-7.5 (0.5-6h) ng/ml respectively.
AUC ( Area Under The Curve)
All AUC values were calculated fiom 0-48 hours post-dosing. The inter-animal 
variation was highest in group 2 (16 mg/kg, 73%). Rat 5 of group 2 had an AUC
3-5 times greater than the other rats within the same dosage group. The median 
AUC value for group 2 was greater (150 ng.h/ml) than either group 3 (110 
ng.h/ml) or group 1 (35.7 ng.h/ml) which were received 32 and 8 mg/kg 
respectively. The median AUC value for group 1 was approximately 3 times lower 
than that of the group 3 and 4 times lower than that of the group 2 (Table 27). A 
comparison of AUC versus dose of 4-OHA administered (Fig. 64) did not suggest 
dose linearity or dose proportionality between the three groups.
Cmax and Tmax
Inter-animal variation with respect to Cmax (Table 27; Fig. 65) was largest in 
group 2 (72%). The highest median Cmax was also obtained in group 2 (Table 27) 
with a value of 16.7 ng/ml (range 7.2-47 ng/ml). Group 3 had a median Cmax of 
8.2 ng/ml (range 4.2-17 ng/ml) while group 1 had a median Cmax of 2.1 ng/ml 
(range 1.9-4.9 ng/ml).
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The median Tmax values for group 2 and group 1 were comparable i.e. 3.5h 
(range 0.5-6.0h) and 4.5h (range 1.0-32.0h) respectively (Table 27). The median 
Tmax for group 3 was slightiy lower at 1.8h (range 1.5-5.0h).
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Comparison of male (Gp 2) and female rats (Gp 4) 
administered 16 mg/kg 4-OHA
It was observed that the consistency of the faeces of the male rats was 
abnormally "loose" while the female faeces was normal.
Serum 4-OHA concentrations in group 4 (female) are shown in Table 26 and 
Fig. 61, and the serum 4-OHA concentrations for group 2 (male) in Table 24 and 
Fig. 59. Median serum 4-OHA concentration profiles for both groups are shown in 
Fig. 66.
4-OHA was detected in the serum of male and female rats at 0.5h after an oral 
dose of 16 mg/kg. The median serum 4-OHA concentration for the female group 
was approximately twice that of the male group at 0.5h with value of 11 ng/ml 
(range 9.3-23 ng/ml) compared to 4.4 ng/ml (range 3.2-22.5 ng/ml) respectively. 
The drug was not detected in the serum of any of the female rats at 32h post-dosing 
but was detected in the serum of all the male rats at 31 and 48h post-dosing.
AUC
The AUC values for both groups of rats were calculated from 0-32 hours. The 
inter-animal variation (Table 28; Fig. 64) was lower in the female group compared 
to the male group (19% and 73% respectively).
The median AUC value for the female group (357 ng.h/ml; range 270-427 
ng.h/ml) was 2.4 times the median AUC for the male group (150 ng.h/ml; range 
83.6-428 ng.h/ml).
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Cmax and Tmax
The inter-animal variation for Cmax was lower in the female group (Table 28; 
Fig. 65) in comparison to the male group (17% and 72% respectively).
The median Cmax (Table 29) for the female group (29.3; range 22-37.8 ng/ml) 
was almost twice that of the male group (16.7 ng/ml; range 7.2-47 ng/ml). 
However, the median Tmax values were comparable (Table 28), with 3.5h (range 
0.5-6.0h) for the male group and 4.0h (range 1.5-7.0h) for the female group.
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3- The chronopharmacokînetics of 4-OHA in the rat 
Introduction
There is considerable evidence that the time of day at which a drug is taken may 
alter its therapeutic and toxic effects. Diurnal variations in the effects of tolbutamide 
(Johnson and Chura, 1974), diazepam (Owasoyo and Walker, 1981) and 
methotrexate (English et al.. 1982) have been reported and, in several instances, 
differences in kinetic behavior have been observed (Vesell et al.. 1977, Marks êî 
al., 1985). This 24 hours study was designed to explore in female rats whether 
time of day has any significance on the drug 4-OHA.
Procedure
Sixteen female rats (Wistar Albino rats), aged between 40-50 days, weighing 
between 150-250g were fed ad libitum and were kept in groups of 4 on a constant 
twelve-hour cycle lightidark (lights on 0630 to 1830) for 5 days prior to the 
experiment. Rats received i.p, 50mg/kg 4-OHA at 0600h, 1200h, 1800h or 2400h. 
The dosing volume used was approximately 0.1 ml. Blood samples from the tail 
vein were collected into heparinised Eppendorf vials at the following time points: 0, 
10,20, 30,45, 60, 90,120 and 180 minutes following drug administration. They 
were spun in a bench centrifuge for 10 minutes and the supernatant plasma was 
transferred into Eppendorf plastic tubes using Pasteur pipettes as soon as possible. 
All plasma samples were stored at -20 until assay for 4-OHA concentration 
using the direct RIA.
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R esults
The results obtained from these experiments showed that levels found in group 
A were very high (0.53-4 pg/ml) in comparison to the other groups (34-82,69-169 
and 14-215 ng/ml for groups B, C and D respectively) but the general pattern 
obtained in all groups was more or less consistent in that several peaks were 
observed in the drug concentration after the administration although the time of 
these peaks differed not only between different groups but also between rats within 
groups. Table 29 shows a summary of the mean of the results obtained from each 
group. These results (Fig. 67) show the following points:
1- The existence of marked variation in plasma concentrations of 4-OHA not 
only between groups i.e. at different dosing time but also within groups.
2- Most groups showed higher plasma concentrations of 4-OHA at 10 minutes 
post-dosing. The relative difference in plasma levels of 4-OHA was most obvious 
in group A (dosed at 0600) and D (dosed at 2400) where the difference was more 
than two fold.
3- The fluctuation in the plasma concentrations of 4-OHA was most apparent in 
groups B (dosed at 1200) and D (dosed at 2400). These two groups showed three 
peaks at almost identical points during the sampling time of 180 minutes (Table 29).
198  Chapter 6
U3
CM I f )  
CO
CO inVO m CMVO at
CM
in inCO O ) CO
CM o  
in
m 00
CM I 
r -  m  
T— CMm
VO o
in 00 CM
e CO
COCM CM
g
I
CO
CM
«Ik
S
Iu
iIV
in r -ro I
VO VO 
CM a t  
CM
in"M* g
avmVO
in VO 
in 1  c~ m 
m in
CM
00
CM at
VOo  -M 
CO g
VO
ov
CM in
O  CM
CO
in
VO
CO
o  7T- 00
CO
« 7
in
CO
in
CO
O g
o  
o  
m CM
O
Oo
<  VO
C9 C
199 Chapter 6
- <  OQ CJ CZJ
C L  C L ,  C L  C L  
3  C* =3 O (D a O 
C. C, (L C. 
C D  C D  C D  c n
;
/
f ' l  I I I— I— r ~ ~ i ---------- 1 ' ■ I I I I I I I— r I   "  f  "I I I I I I I r
CO <N
o  o  a
a
œ
o
CO
a
C4
a
m  0
a
4 — «
H
O
C D
- O  
00
a
o
I U I / 0 U
s [ 0 A 0 i  V H O - ^
•i
bJO
C
II
i
*0
I
c
I
'o
c0
1 
iI
33
I
'o
I’C
I
33
I
cd
"SBI
&
I
2 0 0 Chapter 6
Summary
In this chapter the direct RIA was employed to investigate the pharmacokinetics 
of 4-OHA in rats and rabbits.
The first rabbit experiment indicated a late peak (5 hours after injection) in 
plasma concentration of 4-OHA, whereas the second experiment which used a more 
efficient vehicle for injection showed steady plasma levels, after a similar dose, 
throughout a period of 96 hours post-dosing.
The chronopharmacokinetics experiment showed huge variations between 
individual rats within each group. The variation between groups was more obvious 
between the group of rats which was injected at 0600 on one hand and groups 
injected at 1200, 1800 and 2400 on the other. The group injected in the early 
morning had much higher values than other groups.
The major experiment in this chapter was designed to assess the 
pharmacokinetic differences between male and female rats and if any dose linearity 
and proportionality after oral doses of 4-OHA exists.
4-OHA was detected in the serum of all the animals by 0.5h, irrespective of the 
dose received or gender. For the male rats, AUC and Cmax tended to increase with 
the dose; however variability in the pharmacokinetic data, especially after the 
administration of 16 mg/kg 4-OHA, precluded any conclusion about linearity or 
dose proportionality. The kinetics of 4-OHA appeared to be affected by gender 
(female rats generally had greater AUC and Cmax values than the male rats). The 
serum 4-OHA profiles were too variable between animals and too irregular to 
undertake estimations of the rate of elimination for 4-OHA.
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GENERAL DISCUSSION
4-Hydroxyandrostene-3,17-dione (4-OHA) is a new potent steroidal inhibitor 
of aromatase, the enzyme system responsible for conversion of androgens to 
oestrogens. This drug has been selected from over 200 potential compounds and 
has been used successfully for the treatment of postmenopausal breast cancer. This 
thesis describes the development of a novel, direct RIA for the measurement of 
4-OHA in the plasma using a specific antiserum to the drug its validation and its 
application in experiments designed to obtain further information on the drugs 
pharmacokinetics in rats and rabbits.
In the search for an adequate immunoassay for 4-OHA, the first approach made 
in this study was to test the cross-reactivity of 4-OHA with an AD antiserum, 
available within the department (Guildhay Antisera Ltd, HP/S/665 lA). The 
crossreactivity was found to be as high as 50%, b u t, the idea of using it was 
abandoned in favour of raising specific antibodies against 4-OHA instead. The 
reason for opting for a specific assay rather than using the AD antiserum was 
because of the low plasma 4-OHA levels expected and the anticipation that 
preliminary chromatographic separation of 4-OHA and AD would be necessary to 
avoid interference by AD in the assay. Therefore the 'indirect' assay would be 
more laborious and the recovery of 4-OHA may be subject to sample handling 
errors and large variation between assays. It was, however, interesting to note that 
during the course of the present work such an 'indirect' RIA for 4-OHA has been 
published (Dowsett et al.. 1987). In the absence of a suitable HPLC or GC-MS 
assay, this assay was made use of, in the present study, whenever assay validation 
and comparison was required.
4-OHA is not antigenic by itself because of its small molecular weight. It must 
therefore be linked to a macro-molecule to render it antigenic. The selection of a 
position in the 4-OHA structure in order to link it to a protein was a critical stage in 
the present work, not least because of the specificity required from the antiserum,
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but also because of technical difficulties involved with this compound. Although 
position 4 on the structure of 4-OHA seems to be the easiest way to prepare a 
protein conjugate, this was not even considered because position 4 in ring A is 
vulnerable to conjugation and antisera raised against such a conjugate would be 
unlikely to have a high degree of specificity for the drug. Furthermore, this reactive 
functional group must in fact be kept intact and fully exposed as an antigenic 
determinant if a specific antiserum is to be produced to the drug. All other positions 
on the 4-OHA do not have functional groups , so chemical modification has to be 
introduced into any position which might be used for conjugation other than 
position 4. The most frequently used positions on steroid structures similar to 
4-OHA are position 15 for T (Narasimha et al.. 1976), 11 for AD (Nordblom et al.. 
1984; Besch et al.. 1986), 19 for T (White et al.. 1985) and 7 for AD (Hossain et 
al.. 1976). In the present work, the production of 4-OHA antisera involved the 
preparation of two derivatives of 4-OHA each of which was conjugated onto 
protein at different a site. The first immunoge, 4-OHT-hemisuccinate-17-ovalbumin 
was prepared by inserting a hydroxyl group at position 4 on 
testosterone-hemisuccinate (THS), which is readily available. After that, 
4-OHT-17-HS was coupled to ovalbumin. For the second immunogen,
4-OHA-7a-carboxyethyle thioether, a series of tedious chemical reactions had to be 
carried out for the preparation of this derivative. At each stage, the intermediate 
was isolated and characterized by appropriate methodology. These reactions started 
from AD to give 4-OH-androst-4,6-diene-3,17-dione which was converted to
4-OHA-7a-CET and then linked to ovalbumin using the mixed anhydride procedure 
( chapter 3). The product 4-OH-androst-4,6-diene-3,17-dione was subsequently 
used after additional purification for the peparation of [6,7 ^H]-4-OHA. A 
modification in the chemical procedures of THS epoxidation was introduced.
204  Chapter 7
After conjugation, aliquots of dialysates were examined spectrophotometrically 
at 278nm (the specific absorption band of 4-OH-3-keto steroid compounds) and 
found negative and complete conjugation of the steroid derivative to protein was 
assumed. A molar ratio of 30:1 was thus assumed. Although there is no evidence 
that the titre, affinity or specificity of the antisera is dependent upon the number of 
molecules of steroid in the conjugate, a vaiiaty of ratios were used successfully. In 
one study the number of moles of steroid per mole of albumin has been quoted in 
eccess of 40 for THS (White et al.. 1985).
The selection of ovalbumin as a macromolecule in the conjugation was based 
on the frequent success of its use with small molecules by other workers within this 
department (Aheme et al.. 1982) and also because ovalbum in is phylogenically 
distant from sheep in which the antiserum is raised. This has been proved to be an 
important factor in producing good antibodies titres (Fronstin et al. 1967). Both 
hapten-ovalbumin conjugates synthesized for this study produced the desired 
response in the sheep.
The use of position C-7 in the steroid would have been expected to give a better 
immunogen in regard to specificity because this position is the least likely to 
undergo metabolic changes or to have significant importance as an antigenic 
determinant. In fact , the antiserum which was raised from the immunogen 
conjugated at position 17 was of higher titer and much more specific than the 
antiserum raised against the immunogen conjugated at position 7.
The fact that high cross-reactivity with 4-GHT was shown by the antiserum 
raised against the hapten conjugated at position C-17 could be relevant to the 
question whether antibodies recognize small regions of a steroid molecule or the 
overall steroid structure (Pressman and Grossberg, 1970). From the results 
presented here it appears that the A ring of 4-OHT had a major role as an antigenic
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determinant, hence the lack of cross-reactivity with AD. In addition, the C-17 
position is also involved as evident in the significant binding of this antiserum with 
4-OHT.
On the other hand, the antiserum raised against the hapten conjugated at position 
C-7 showed a high cross-reactivity with AD, but not 4-OHT. Such absence of any 
significant cross-reactivity with 4-OHT appears to be in accordance with the 
previous finding of the 17-oxo functional group as a key antigenic determinant on 
AD (Milewich et al., 1975). The reactivity of this antiserum with AD implies that 
the 4-OH region may somehow play a lesser role in eliciting immune response 
when a macromolecule is present in the C-7 position of the hapten.
As it has been observed before (B.A.Morris, personal communication), an 
interval between the primary and booster doses of the immunogen, allowing serum 
antibody to fall sufficiently to a low steady level, was a common feature to the 
successful immunisation protocols used here. Indeed, the antisera obtained against 
4-OHA were both of high specificity and high titre and avidity.
The RIA described here allows the measurement of 4-OHA in plasma at 
concentrations down to 25 pg/ml, with adequate accuracy and precision. Within the 
assay system, there is still room for increasing the sensitivity, but considering the 
limited available information on plasma 4-OHA levels in patients, that seemed 
hardly necessary. After a 250 mg dose of 4-OHA given by mouth, the highest drug 
concentrations were found after 1 to 3h with a mean ± s.e. value of 44.4 ±7.2  
ng/ml (Dowsett et al.. 1987). By 24h, the drug was either undetectable (<0.3 
ng/ml) or present in plasma at a level of 0.8 ng/ml. Also , two weeks following 
500 mg intra-muscular injection, 4-OHA persisted at 0.5 ng/ml level. Unlike the 
other published method for 4-OHA (Dowsett et al.. 1987), the present RIA can be 
applied directly on neat plasma samples of less than 50pl volumes without any
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interference from the matrix.
The comparative assays of plasma samples and organic extracts of plasma 
samples have indicated that only unconjugated steroids are analysed by this RIA. 
This is important , because 4-OHA glucuronide has been reported to be the 
principle urinary metabolite. A plethora of oxidation and reduction products are 
formed from 4-OHA by isolated rat hepatocytes and these, together with the parent 
compound as the major component, are rapidly converted to glucuronide conjugates 
(Foster et al.. 1985). In fact, it could be predicted that 4-OHA-glucuronide which 
is metabolised at position 4 (the main antigenic determinant) would not interfere 
with the antisera. 4-OHT, a putative metabolite of 4-OHA, was identified by 
GCMS as the major metabolite in rat ovarian microsomal incubations (March et al.. 
1982) accounting for 20% of the total radioactivity from [6,7-^H]-4-OHA. 
Whether the 60% cross-reactivity of 4-OHT with the antiserum HP/S/1513 puts 
constraints on the use of this RIA for 4-OHA must await a clearer understanding of 
4-OHA metabolism in the human. However, 4-OHT accounted for less than 1% of 
the total blood radioactivity after injecting ^H-4-OHA intravenously to two male 
rhesus monkeys (Brodie et al.. 1981) and only 0.1% in the rat (March et al.. 1982). 
Furthermore, in a recent study, 4-OHT was not detected as a metabolite either as a 
conjugate or free steroid (Foster et al.. 1986).
When the present RIA was studied for possible interference from 4-OHT, no 
evidence was found to suggest the presence of this compound in the clinical 
samples as a metabolite to any significant extent. This conclusion was reached by 
using two different antisera, HP/S/1513 lA and HP/S/665 lA. As the first 
antiserum cross-reacts by 60% with 4-OHT and the second by only 0.1% , the 
analysis of column fractions relevent to the position of 4-OHA by both antiserum 
gave similar quantitative values in terms of immunoreactivity, thus, supporting the 
view that only 4-OHA is being measured. All column chromatographic separations
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of extracts of clinical samples and plasma enriched with appropriate steroids prior to 
monitoring the collected fractions for radioactivity or immunoreactivity, as may be 
relevant, showed that the magnitude of any interference with the assay by the 
relevant steroids could only be minimal.
An important determinant of drug disposition and clinical efficacy would be the 
extent to which the drug binds to plasma proteins. Various endogenous C-19 
steroids, such as testosterone, present in plasma highly (approx. 97%) bound to 
proteins (Vermeulen, 1973). The experiments carried out in the present work 
showed that 4-OHA was bound to plasma proteins to a lesser extent than the 
endogenous androgens; it showed that 4-OHA was 6-7% and 13-16% in the free 
form in plasma at 4 °C and 20 °C respectively. One possible explanation for this 
difference may be that the presence of the hydroxyl group at position 4 had 
negatively affected the binding of 4-OHA to the specific proteins to which 
androgens are usually bound i.e SHBG and CBG. This could have created a slight 
conformational difference in the steroid structure and subsequent loose' binding to 
proteins. The fact that more 4-OHA is available in the free form may have positive 
clinical implications as far as the pharmacology of the drug is concerned and may 
mean lower doses of drug are needed. Moreover, the availability of relatively high 
proportions of 4-OHA in the free form could mean that salivary levels rather than 
plasma levels could be used in clinical studies. The relationship between steroid 
concentrations of the free (unbound) active fraction in plasma and its presence in 
saliva is well established (Riad-Fahmy et al.. 1982).
»
Although it is possible to produce monoclonal antibodies against steroids which 
are suitable for RIA and which offer high specificity and unlimited supplies, 
conventional polyclonal antibodies were chosen in this work, because they are 
likely to give adequate results for less investment and effort. Two other serious 
problems in the application of monoclonal antibodies to steroids RIAs have also
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limited its selection here. Firstly, it is unlikely that the cross-reactivity of 
monoclonal antibodies with other steroids would be any less than with a specific 
polyclonal antiseram. As the name implies, monoclonal antibodies are produced by 
one clone of cells derived from a single lymphocyte and are directed against, the 
same structural feature i.e. 'epitope' which may also be found in many other 
steroids. Secondly, when producing murine monoclonal antibodies for steroids, it 
is likely that the antibodies would be of low affinity (Groves et al.. 1987) This is 
because the the majority of lymphocytes produce antibodies of relatively low 
affinity for their antigen. So the chance of producing a high affinity monoclonal 
antibody is not great. These dangers appear to be minimized in conventionally 
produced polyclonal antisera in which there is a heterogeneous population of 
antibody molecules of different affinities. Also by using appropriate polyclonal 
immunization schedules the antibodies produced have very often high avidity and if 
the animal used in the immunization is large e.g. a sheep, then adequate supplies 
from one bleed for large number of assays can be obtained. This was the case with 
HP/S/1513 lA where a single bleed contained enough antibodies to assay more 
than 20 mi|ion samples in duplicate!.
Using the novel polyclonal antisera produced to 4-OHA, an assay has been 
developed and proved to be accurate, robust and reproducible. The tritiated form of 
4-OHA used had provided a suitable label, but since it is not generally available, 
further work to produce a nonisotopic assay is required. Some attempts were made 
to use a chemiluminescent endpoint to assess the possibility of developing a 
non-isotopic assay for the measurement of 4-OHA.
A solid phase antigen competitive assay format was used, and althouth 
reasonable displacement was obtained in some cases, this unfortunately did not lead 
to acceptable standard curves. Because of shortage of time further developmental 
work was not attempted. A noticeable 'between assay' variation was observed
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throughout the experiments. This may be a problem in luminescence 
immunoassays because more steps and careful timing of reagents additions are 
required and also because "early" bleeds of A/S were used. These problems, 
however, have been greatly diminished with the development and use of enhanced 
lumuinescence and acridinium esters (Weeks et al.. 1983).
Enhanced chemiluminescence (Thoipe and Kricka, 1986) could have offered a 
better chance than procedures adopted in this work. However,this technique was 
not widely common at the time and therefore was not followed. The enhanced 
chemiluminescence technique is based on the use of horseradish peroxidase labels 
which react with a mixture of luminol (or isoluminol), peroxide and an enhancer 
such as p-iodophenol. Peroxidase acts catalytically in the chemiluminescent 
oxidation of luminol by peroxide and the enhancer acts synergistically to increase 
the magnitude of light emission. A characteristic of enhanced chemiluminescent 
reactions is that the light emission is intense and prolonged as opposed to the 
short-lived (=10s) luminescence normally achieved with luminol. Therefore, 
increased sensitivity and ease of measurement is obtained with enhanced assays. 
This feature may well prove useful in the development of a non-isotopic 
immunoassay for 4-OHA.
Pharmacokinetic studies in animals were carried out once the developed RIA 
had been validated. These studies were carried out using rats and rabbits. The 
contrasting results obtained from the rabbit experiments may be explained either by 
the nature of the vehicles used to inject 4-OHA into the rabbits i.e. efficiency or by 
assuming that the drug has a depot effect It could be argued that the late peak (after 
5h) in the plasma concentration of 4-OHA is the result of biliary excretion of the 
glucuronide form of the drug and reabsorption after hydrolysis. However, the low 
concentrations of 4-OHA found in the plasma confirm the suggestion that 4-OHA is 
rapidly and extensively conjugated.
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The chronopharaiacokinetic studies in the rat showed great variations in 4-OHA 
plasma concentrations, not only between different groups but also within each 
group. The possibility of interference from unknown metabolites can not yet be 
ruled out. However, the most obvious observation was the higher values of 
plasma 4-OHA concentrations obtained in rats administered the drug at 0600. 
E xperience with prednisolone within this department (English et al.. 1983) 
revealed similar findings. This and the well known circadian rhythms in 
endogenous steroid hormones (Rebar and Yen, 1979) may suggest important 
implications in regard to the optimum timing of 4-OHA in clinical practice. 
However, the rhythmic variation in hepatic microsomal steroid metabolism (Lake et 
Mm 1976) should be considered as a possible factor influencing the diurnal variation 
in the pharmacokinetics of 4-OHA in rats.
Rats given the drug orally showed that 4-OHA was rapidly absorbed by both 
sexes, appearing in the serum by 0.5h after administration, irrespective of the dose 
of 4-OHA given. However, large variations between individual and different 
groups was observed, although, within the female group, the inter-animal 
variations were less marked. This might be the consequence of an apparent sex 
difference in the action of 4-OHA in the gastrointestinal tract. Gower (1984) 
concluded that in rats, there are sex differences in the hepatic metabolism of 
steroids, male rats showing a higher hydroxylating activity than females.
In male rats the AUC and Cmax generally increased with an increase in the 
dose. Variability in the pharmacokinetic data, however, precluded any conclusion 
about dose linearity or proportionality. The failure of the 32 mg/kg dose to produce 
a proportional increase in AUC and Cmax values may be attributed to a 
corresponding enhancement of 4-OHA interaction with intestinal absorption.
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Studies using male and female rat groups given the same dose of 4-OHA (16 
mg/kg) indicate that the drug has different kinetics depending on gender. Female 
rats generally appeared to have a more rapid rate of absorption and elimination than 
the males. The female also had greater Cmax and AUC values.
In a report from Ciba-Geigy where a comparison of the dose excreted via urine 
and faeces p.o. administration of [6,7-^H]-4-OHA to male and female rats has 
shown that nK>re faecal excretion of radioactivity occurred in males than in females. 
This may explain the findings in this study of abnormally loose faeces for the male 
rats but not for the females. It is obvious, therefore, that further information on the 
pharmacokinetics of 4-OHA in both experimental and clinical situation is required. 
Pharmacokinetic parameters need to be related to pharmacological effects e.g. extent 
and duration of oestrogen suppression.
In conclusion, the RIA developed here represents an important step in the 
development of 4-OHA for therapeutic purposes. Being a direct, sensitive and 
robust assay, it has the potential to become an integral part of future clinical trials of 
4-OHA, and would have important clinical and experimental uses. A sensitive and 
reliable method for the measurement of 4-OHA should also facilitate more extensive 
clinical pharmacokinetic studies designed to optimise the dose and route of 
administration of the drug and to devise the most effective therapeutic regimen for 
this dmg.
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Antibodies to d-hydroxÿandrpstenedione -  a nevg ànti-breast ùanceir 
agent suitable for use in a radioimmunoassay ’ ^
J . Khubieh, G. W . Aherne, and J. Chakraborty
Division o f  Clinical Biochemistry, Department o f  Biochemistry, University o f  Surrey, Guildford, Surrey G U2 5XH UK
Summary. A  specific  antiserum  suitable for radioim m u­
noassay (R IA ) o f  4-hydroxy-4-androstene-3,17 d ione  
(4-O H A ) has been developed . Sheep antiserum  w as raised  
by injecting tw o different conjugates prepared by coupling  
4-O H A  to ovalbum in. A ntisera obtained from  a sheep im ­
m unised w ith 4-hydroxy-testosterone-17-hem isuccinate  
ovalbum in conjugate were o f  higher titre and m ore sp ecif­
ic  than antisera obtained from  sheep im m unised with 4-hy- 
droxyandrostenedione-7a-carboxyethylth ioether. The an­
tiserum  bound 50% o f  20 picogram s o f  [6,7-^H]-4-OHA at 
an initial d ilution o f  1:270. The m ost relevant steroids, an­
drostenedione (A D ) and testosterone (T) were tested and  
show ed cross reactivity o f  2.7% and 5.1% respectively. The 
low er lim it o f  detection  was 4.5 p g /tu b e . A ntisera from  
this anim al w ill prove usefu l as the basis o f  a sensitive and  
specific  R IA  for clin ical pharm acokinetic studies o f  
4-O H A .
Introduction
4-H ydroxyandrostenedione (4-O H A ) is a potent and selec­
tive inhibitor o f  the enzym e com plex arom atase (oestrogen  
synthetase). It has im portant applications as a research  
too l for investigating oestrogen-m ediated processes [2, 6], 
and also great potential c lin ical value for controlling tu­
m ours w hich are oestrogen-dependent [8]. A  phase II study  
o f  the drug has been published [4] recently, w hich confirm s 
the b io logical activity o f  4-O H A  in advanced post-m eno- 
pausal breast cancer. Plasm a levels o f  4-O H A  w ere m ea­
sured in this study using a radioim m unoassay (R IA ) for  
androstenedione after chrom atographic separation o f  
4-O H A  from  androstenedione and utilizing antibodies 
w ith a 25% cross-reactivity w ith 4-O H A . U p  to date no re­
ports o f  the production o f  specific antisera to 4-O H A  have 
been published. W e report here the production o f  sp ecific  
antibodies to 4-O H A  in sheep.
M aterials and methods
4-H ydroxyandrostenedione w as kindly supplied by Ciba- 
G eigy, Basel, Switzerland. Other steroids w ere purchased  
from  Sigm a C hem icals Ltd. Tw o ovalbum in im m unogens
Offprint requests to: J. Khubieh
w ere prepared and injected in to  anim als. 4-O H  testoster­
one-17-hem isuccinate (4-O H T H S) was prepared from  tes­
tosterone-.! 7-hem isuccinate by hydroxylation  at C -4 [1] 
and conjugated to ovalbum in usipg the m ixed anhydride  
m ethod described by Erlanger et al. [3], For the secon d  im ­
m unogen, androstenedione was converted to 4-hydroxyan- 
drosta-4,6-d iene-3,17-dione [7], and then to 4-hydroxyan- 
drostenedione-7a-carboxyethylth ioether (4-O H A -7aC E T ) 
[5] before conjugating to ovalbum in. Each conjugate was 
in jected into tw o sheep using a conventional im m unisation  
schedule. [6,7-^H]-4-OHA w ith sp ecific  activity o f  15.6 Ci 
m m ol" ' was prepared [7] and used , after purification on a 
silica gel chrom atography colum n, to assess the b inding  
capacity o f  the antisera. Standard R IA  procedures w ere 
em ployed. Tritium -labelled 4-O H A  (20 pg)wvas incubated  
for 1 h at room  tem perature w ith d ilu tions o f  antisera. The  
diluent buffer was 0.05 M  phosphate saline, pH  7.2, co n ­
tain ing 0.1% sodium  azide and 0:1% gelatin. Separation o f  
the free and antibody-bound fractions o f  the tracer was 
achieved with 2.5% dextran-coated charcoal.
Results
A ntisera obtained from  a sheep  (H P /S /1 5 1 3 ) im m unised  
w ith 4-O H T H S ovalbum in conjugate w ere o f  higher titre 
(1:270) and m ore sp ecific  than those obta ined  w ith  
4-O H A -7a-C E T -ovalbum in . A  calibration curve (F ig. 1) 
w as produced using this antiserum  and 100-pl aliquots o f  
standard 4-O H A  (50 pg to 10 n g /m l). The theoretical sen ­
sitivity o f  the assay w as 45 p g /m l, and the w ith in-assay  
coefficien t o f  variation, 5.1%, at a standard concentration  
o f  200 p g /m l. Initial studies have show n that the anti­
bod ies from  H P /S /1 5 1 3  cross-reacted w ith and rostened i­
one by 2.7% and w ith testosterone by 5.1%.
Discussion
A n antiserum (H P /S /1 5 1 3 ) suitable for use in  an R IA  for 
the m easurem ent o f  4-O H A  was obtained  10 w eeks after 
the prim ing injection  o f  4-O H T H S-ovalbum in . A s m ight 
have been  predicted [5], its specificity  tow ards closely  re­
lated steroids was higher than that o f  antisera produced  to  
4-O H A -7aC E T . The sensitivity o f  the curve obtained  is 
sufficiently  high to a llow  the m easurem ent o f  the p lasm a  
4-O H A  concentrations expected  (0 .7 -2 3 .2  n g /m l)  [4] dur­
ing clinical use. Further plasm a sam ples resulting from  H P /  
S/1513 obtained follow ing a second im m unization are
176
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Fig. 1. The mean ( ± S D )  o f  five separate 4-OHA standard curves; 
20 pg ^H-4-OHA/tube; antiserum dilution 1:270; non-specific  
binding 4%; zero-concentration binding (B J 40%
now  available for investigation , and work is in progress to 
characterise these antibodies further w ith regard to the m e­
tabolites o f  4-O H A  and to validate an R IA  suitable for the 
analysis o f  clin ical sam ples.
The availability  o f  an assay using antisera described  
here should facilitate m ore extensive clin ical pharm aco­
k inetic studies designed  to optim ise the dose and route o f  
adm inistration o f  4-O H A  and to devise the m ost effective  
therapeutic regim en for this drug.
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A DIRECT RADIOIMMUNOASSAY (RIA) FOR 4-HYDROXY- 
AND'ROSTENEDIONE MEASUREMENT IN PLASMA
J. Khubieh*, W. Aherne and J. Chakraborty. Biochemistry Department* University 
of Surrey, Guildford GU2 5XH, Surrey.
4-Hydroxyandrostenedione (4-OHA) is a potent and specific inhibitor of aromatase 
which mediates the conversion of androgens to oestrogens, and has been successfully 
used for the treatment of breast cancer. Plasma levels of 4-OHA (0.7 - 23.2ng/ml) 
have been measured in a Phase II study I Goss, P.E. et. d .  1986 Cancer Res. 
48233 by adapting an RIA for androstenedione which cross-reacts by 25% with 4- 
OHA. We report here the characteristics of an RIA using a specific antiserum to 4- 
OHA, and a tritiated label (15.6 Ci/mmol) for direct plasma assay a t the low 
concentrations expected. The standard curve ranges from 5Gpg/mI to 5ng/ml with a 
lower lim it of detection of G.25ng/ml. Inter-assay variation of a pooled patient 
sample measurement was 6% (37.6ng/ml + 2.32). Complete recovery of 4-OHA added 
to normal female plasma was obtained a t concentrations of Ing/ml to 2pg/ml. 
Analysis of patient samples and normal plasma enriched with 4-OHA showed that up 
to 87% of plasma 4-OHA was bound to proteins.
The antiserum cross-reacts with androstenedione, testosterone, 3g-hydroxy-5a 
androstan-4,17 dione, 4-hydroxy-oestrone, 4-hydroxy-oestradiol and cortisol by G.9, 
2.4, G.6, 0.3, G.5 and 0.3% respectively. RIA of 4-OHA in plasma samples carried out 
in conjunction with solvent extraction and Lipidex 5000 chromatography confirmed 
th a t there was no interference from androstenedione. However, 4- 
hydroxytestosterone (4-OHT), a putative metabolite of 4-OHA, cross-reacts by 
100%. The RIA, will not only be useful for pharmacokinetic studies of 4-OHA, but, 
combined with Lipidex 5000, will provide a means of determining the extent and 
tim e course of metabolism to 4-OHT.
